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ABSTRACT 
The Association of Demographics, Social and Personal/Family Characteristics with Treatment 
Utilization Among Young Adults with Opioid Use Disorder in the United States 
by 
Marva Leonora Frederick, MSN, MA, RN 
Advisor: Dr. Linda Scheetz 
Background 
Opioid use disorder is a life-threatening medical condition and an ongoing public health 
problem in the United States.  Treatment is necessary to combat opioid use disorder and to 
minimize the health-associated problems.  Opioid use disorder is treatable with life-extending 
medications.  Studies that examined treatment utilization among young adults with opioid use 
disorder in the United States was scarce.  This study investigated the characteristics posited in 
the Andersen Behavioral Model of health utilization which may be associated with treatment 
utilization, among young adults with opioid use disorder in the United States.  The urgency 
posed by the continuing opioid crisis in the United States underscores the timeliness of this 
study.  The research question was: What is 
 the predisposing, enabling, and needs characteristics as posited in the Andersen 
Behavioral Model that are significantly associated with treatment utilization among young adults 
with opioid use disorder in the United States?   
Theoretical Framework 
The Andersen Behavioral Model of health utilization guided the study.  The Andersen 
Behavioral Model posited multiple population characteristics which may be associated with 
treatment utilization. 
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Methods 
A secondary analysis of the 2017 National Survey on Drug Use and Health dataset was 
conducted.  Records of young adults with a diagnosis of opioid use disorder (n = 1,021) were 
filtered from the secondary dataset.  A dichotomous variable in the dataset, treatment utilization, 
served as the outcome variable.  Covariates were derived from the predisposing, enabling and 
needs characteristics posited in the Andersen Behavioral Model, and available in the secondary 
dataset.  A hierarchical binary logistic regression model was used to analyze the association 
between potential covariates and treatment utilization for opioid use disorder.   
Results 
The most concerning finding was that more than 90% of this study’s sample did not 
utilize treatment.  Further, young adults were more likely to utilize treatment if they had an arrest 
history.  Significant associations were observed with the predisposing characteristics 
race/ethnicity, employment status, and household size. 
Conclusion 
To plan effectively and comprehensively, and to formulate strategies for enhancing 
opioid use disorder treatment utilization among young adults in the United States, it may be 
necessary to fully explore the population characteristic arrest history, in addition to other 
significant associations reported.  Existing treatment strategies should be assessed to determine 
their usefulness and efficiency. 
Keywords: opioid use disorder, treatment utilization, young adults, Andersen Behavioral 
Model, logistic regression 
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Chapter 1: Background and Study’s Purpose 
Background and Problem 
Results from the National Survey on Drug Use and Health (NSDUH) revealed that young 
adults in the U.S. had a greater prevalence of substance use compared to older adults in the years 
2016 and 2017 (Ahrnsbak, et al., 2017; Bose, et al., 2017, 2018).  The difference in prevalence 
between the two years had changed minimally.  One in seven young adults or 5.3 million 
(15.5%) was reported as needing substance use treatment in 2016.  In 2017, the number of young 
adults needing substance use treatment remained at one in seven or 5.2 million (15.1%).  
Conversely, older adults needing substance use treatment in 2016 was reported at 14.5 million 
(6.9%) compared to 14.5 million (6.8%) in 2017.  Consistent with previous research, needing 
substance use treatment in this study was interpreted as having a substance use disorder (SUD) 
or having received substance use treatment in the past year (Bose, et al., 2017; Lipari, et al., 
2016).  SUD in the 2017 NSDUH dataset, was based on the diagnostic criteria for substance 
dependence/abuse specified in the Diagnostic and Statistical Manual of Mental Disorders IV 
(DSM-IV; American Psychiatric Association, 1994), as shown in Tables 1 and 2.  SUDs 
encompass alcohol use disorder (AUD) and drug use disorder relating to misuse of prescription 
opioids, stimulants, sedatives,  inhalants or use of methamphetamine, tranquilizers, marijuana, 
cocaine (including crack), hallucinogens, heroin (Park-Lee, et al., 2017; Substance Abuse and 
Mental Health Service Administration [SAMHSA], 2018d).  Opioid use disorder (OUD) was 
classified by NSDUH as an individual meeting the DSM-IV criteria for pain reliever use disorder 
and/or heroin use disorder in the past year (Bose, et al., 2017, 2018; SAMHSA, 2018d).  This 
study focused on OUD (a subtype of SUD) among young adults.  Young adults were classified as 
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an individual 18 - 25 years old.  An older adult referred to an individual > 25 years and an 





Criteria for Substance Dependence (excludes alcohol) 
- Based on DSM-IV Criteria: Three or More 
Occurring Within a One-Year Period 
  
 
Criteria for Substance Abuse (excludes alcohol) - 
Based on DSM-IV Criteria: One or More 
Occurring Within a One-Year Period 
 
•  • substance tolerance due to (a) a need for 
increased amounts of the substance, or (b) 
continued use of the same amount with 
diminished effect 
 • continued substance use despite adverse 





• characteristic withdrawal syndrome for the 
substance, or the same (or closely related) 
substance was taken to relieve or avoid 
withdrawal symptoms 
 • repeat inability to fulfill major 
obligations at work, school, or home 
 
• 3 • taking a substance in larger amounts or over 
a longer period than intended 
 • repeatedly putting oneself or others in 
physically harmful situations. 
 
•  • persistent desire or unsuccessful efforts to cut 
down or control substance use 
 • repeated substance-related legal 
problems. 
 
•  • excessive amounts of time spent in obtaining 




•  • continued substance use despite adverse 
recurrent social/interpersonal problems 
 
•  
•  • awareness of persistent physical or 
psychological problems likely caused by 
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 Table 2 
Criteria for Alcohol Use Disorder Used in the 2015 Through 2017 NSDUH Based on DSM-IV Criteria 
 
• spent a lot of time engaging in activities related to alcohol use 
• used alcohol in greater quantities or for a longer time than intended 
• developed tolerance 
• made unsuccessful attempts to cut down on use 
• continued use despite physical health or emotional problems associated with alcohol use 
• reduced or eliminated participation in other activities because of alcohol use 
• experienced withdrawal symptoms when cutting back or stopping use 
 
Among the 5.3 million young adults who needed substance use treatment in 2016, 
approximately 2.5 million were treatment-eligible for an illicit drug use problem, with 
3.8 million treatment eligible for an alcohol use problem (Park-Lee, et al., 2017).  Results from 
2016 NSDUH, estimated that only 383,000 (7.2%) of these young adults, received SUD 
treatment at specialty substance use treatment facilities compared to 1,756 (12.1%) older adults 
(Park-Lee, et al., 2017).  A specialty treatment facility was defined by NSDUH as treatment 
received at drug or alcohol rehabilitation facilities (inpatient or outpatient), hospitals (inpatient 
services only), and mental health centers (Bose, et al., 2017).  Compared to older adults with 
SUD, a larger proportion of younger adults with SUDs needed treatment; however, a much 
smaller proportion received treatment.  Therefore, given the notable disparity between younger 
and older adults regarding treatment needs for SUD compared to treatment receipt for SUD and 
considering that persons with OUDs are a subset of those with SUDs, it was reasonable to 
suspect that these disparities were similar among young adults with OUDs.  Limitations in the 
Park-Lee and colleagues’ (2017) reporting on treatment needs and treatment receipts was the 
exclusion of statistical significance levels and mean of estimates, in addition to exclusion of 
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specific treatment types utilized.  Bose and colleagues (2018) reported similar disparities 
between young adults and older adults related to SUD treatment needs and the receipt of 
substance use treatment.   
Among the various SUDs, OUD accounted for the highest SUD mortality rate 
(Bose, et al., 2017; Lipari, et al., 2016).  Opioids encompassed a class of drugs that included the 
illicit drug heroin and the licit prescription pain relievers oxycodone, hydrocodone, codeine, 
morphine, fentanyl, and others (Kolodny, et al., 2015; NIDA, 2018a, 2018b).  Opioids interact 
with opioid receptors on nerve cells in the brain to produce feelings of euphoria and relieve pain, 
and can be highly addictive. 
Comorbidities and Concurrent Use of Substances   
Two major concerns with the problem outlined earlier was the occurrence of 
comorbidities and the concurrent use of substances.  SUDs had been reported to occur in 
conjunction with mental and/or medically related comorbidities (Ali, et al., 2015; Butler, et al., 
2017; Defoe, et al., 2019; Haughwout, et al., 2016; Jones, et al., 2017; Rodriguez-Sejias, et al., 
2017; Romo, et al., 2018; Wu, et al., 2016; Tragesser, et al., 2013).  Mental comorbidities 
included anxiety, mood, and behavioral disorders.  Tragesser and colleagues, 2013 reported that 
features of bipolar personality disorder (self-harm/impulsivity) were primarily associated with 
opioid misuse.  Common medical comorbidities which may occur with SUDs, included human 
immunodeficiency virus infection, acquired immune deficiency syndrome, viral hepatitis 
infections, and respiratory deficiencies (Kosten, & George, 2002; SAMHSA, 2015; CSUP, 
2016).   
Apart from mental and medically related comorbidities, concurrent substance use was 
commonplace (Cohn, et al., 2018; Jones, et al., 2014; Wu, et al., 2011, 2016).  Correlations had 
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been found between the use of illicit substances and alcohol, among young adults and among 
older adults (Cohn, et al., 2018; Jones, et al., 2019).  In addition, multivariable models were 
applied showing substance use problems associated with alcohol, cigarettes, and marijuana use.  
The Focus on Opioid Use Disorders Among Young Adults   
This study focused on treatment utilization among young adults with OUD in the U.S.  
OUD was described as a life-threatening medical condition and a major public health problem in 
the U.S.  In 2017, an estimated 445,000 (1.3%) young adults compared to 1.6 million (0.7%) 
older adults had an OUD (Table 3).  This meant that young adults had the most prevalent OUD 
treatment needs between these two groups (Bose, et al., 2018).  In addition, as OUD is a subtype 
of SUD, it should be noted that only 641,000 of 5.2 million (12.6%) of young adults who needed 
SUD treatment received treatment (Bose, et al., 2018).  It was therefore important to conduct this 
study to identify population characteristics significantly associated with treatment utilization 
among young adults with OUD in the U.S.  Knowing the associated population characteristics, 
may provide insight into those at highest risk for non-use of OUD treatment. Other concerns with 
OUD related to (a) comorbidities associated with SUDs, (b) concurrent substance use, (c) OUD 
having the highest mortality rate compared to other SUDs, and (d) not finding data specific to 
treatments needs and treatment receipts among young adults provided.   
Medications for Opioid Use Disorder   
The gold standard treatment for combating OUD was pharmacotherapy, in conjunction 
with counseling and/or behavioral therapies (Abraham, et al., 2017; FDA, 2018; Sofuoglu, 
et al., 2018).  There was no consensus on the ideal length of time for pharmacotherapy, however, 
better health outcomes had been reported, when pharmacotherapy was used for longer periods. 
 





 Substance Use Disorders in 2017 Among the U.S. Population by Age Group: (thousands and percent) 
 
 Substance use disorders  Young adults  Older adults  
Alcohol use disorder  3.4 million (10.0 %) 10.6 million (5.0%) 
Marijuana use disorder 1.8 million (5.2%) 1.7 million (0.8%) 
Prescription pain relievers 445,000 (1.3%) 1.6 million (.7%) 
Prescription pain reliever use disorder 339,000 (1.0%) 1.2 million (0.6%) 
Tranquilizer use disorder 278,000 (0.8%) 380,000 (0.2%) 
Cocaine use disorder 243,000 (0.7%) 703,000 (0.3%) 
Methamphetamine use disorder 188,000 (0.5%) 751,000 (00.4%) 
Stimulant use disorder 187,000 (0.5%) 323,000 (0.2%) 
Heroin use disorder 165,000 (0.5%)  483,000 (0.2%) 
 
Bose, et al., 2018 study “Key Substance Use and Mental Health Indicators in the United States: Results 
from the 2017 National Survey on Drug Use and Health”. https://www.samhsa.gov/data/sites/default/ 
files/cbhsq-reports/NSDUHFFR2017/NSDUHFFR2017.pdf 
  SAMHSA and NIDA recommended continuous treatment with MOUDs to ensure 
effective treatment (SAMHSA, 2019d).  Counseling and behavioral therapies aided in adherence 
to MOUDs, which in turn, prevented relapse.  MOUDs had not always been accessible to the 
population that misused substances (Belenko, et al., 2013; Hadland, et al., 2018).  In the U.S. 
criminal justice system for example, most individuals entering the system was reported to be 
misusing substances at the time of arrest (Belenko, et al., 2013; Bureau of Justice Statistics, 
2020; National Institute of Correction 2017, n.d.).  The criminal justice system had various 
substance abuse treatment programs (alternative-to-prison, community-based supervision, 
community-based treatment, prison-based treatment).   MOUDs, however, was in limited use in 
the criminal justice system due to the reported stigma associated with opioid substitution therapy, 
the availability of resources to provide pharmacotherapy (financial, staffing), and possible risk of 
diversion of treatment medications for illicit use. 
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MOUDs Clarified.  The U.S. Food and Drug Administration (FDA) approved the 
following MOUDs: buprenorphine (BUP), methadone (METH), and naltrexone (NALT) 
(SAMHSA, 2019b).  METH is a full mu-opioid opioid (μOR) agonist and works by binding to 
and activating all opioid receptors.  NALT, a μOR antagonist, binds to and blocks all opioid 
receptor sites.  BUP is classified as a partial μOR agonist and works by binding to μORs while 
reducing the overstimulation of the receptors (Chan, et al., 2020; Chen, et al., 2013; FDA, 2018; 
D’Onofrio, et al., 2017; Greenwald, et al., 2014; Jones, et al., 2015a; Jones, et al., 2015b; 
Mattick, et al., 2014; Medscape, 2020; NIDA, 2017b; SAMHSA, 2019a, 2019c; Smith, 2014; 
Stone, et al., 2018; White, et al., 2014).  A comparison of the three FDA-approved MOUDs is 
shown in Table 4.   
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Table 4  
A Comparison of Medications for Opioid Use Disorder: Buprenorphine, Methadone, Naltrexone 
   Buprenorphine (BUP) Methadone (METH) Naltrexone (NALT)  
 Action 
a partial mu-opioid receptor (μOR) agonist 
for treating OUD 
a full μOR agonist for treating OUD it is a μOR antagonist.   
  it binds to and reduces. the overstimulation of 
the receptors 
it binds to and activates all receptors. 
it works by binding to and blocking 




Outcome of use reduces opioid withdrawal symptoms and use 
of illicit opioid use 
reduces opioid withdrawal symptoms and 
use of illicit opioid use 
reduces illicit opioid use  
 




can be prescribed by a qualified physician, 
physician assistant or nurse practitioner in a 
certified opioid treatment program (OTP) or 
office-based practice 
must be administered each day at a 
specially licensed clinic 
can be prescribed by a qualified 
physician, physician assistant or 
nurse practitioner in a certified OTP 
or office-based practice 
 
 
Formulation it is available as a sublingual film, extended-
release injectable, subdermal implant 
it is available as a tablet, or oral solution it is available as an extended-release 
injection or in daily oral formulation 
 
 
 special training/waiver requirement needed to 
prescribe BUP 
no special training or waiver requirement 
to prescribe METH 
no special training or waiver 
requirement to prescribe NALT 
 
 
Average dosage average dose ranges from 1-2 mg to 
16-32 mg 
 
the average dosage is 40mg; dosing starts 
at 10 to 20 mg and increase in 10mg 
increments until the withdrawal symptoms 
are controlled 
the dosage is 50mg, 25mg over two 
days orally/day, or 0.2mg 
increments up to 0.8mg injectable 
 
 Diversion of drug potential for diversion to non-medical use potential for diversion to non-medical use ̶  
 Ceiling effect of drug 
it has a ceiling effect (lowers the risk of 
misuse, and side effects on respiration) 
it has no ceiling effect (unless individual is 
dependent on high doses of opioids and 






retention rates at approximately 93% were 
reported for extended-release (XR) 6-month 
BUP implants and for daily formulations in 
an outpatient specialty treatment center 
an 89% retention rate was reported in a 
single methadone treatment program 
between, November 1st, 2016, and August 
31st, 2017, in Rhode Island 
retention rates at approximately 
53% were reported for the XR 
formulation in an inpatient/ 
outpatient specialty treatment center 
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Prescribing and administering standards for MOUDs had impeded its access (Anderson 
& Kearney, 2000; Chen, et al., 2013; FDA, 2018; Greenwald, et al., 2014; Jones, et al., 2015a; 
Jones, et al., 2015b; Mattick, et al., 2014; McNicholas, 2004; Medscape, 2020; NIDA, 2017b; 
SAMHSA, 2019a, 2019c, 2019d; Smith, 2014; White, et al., 2014).  To prescribe BUP for long-
term opioid treatment, physicians in opioid treatment clinics and office-based facilities needed 
special waivers (SAMHSA, 2019c; The President’s Commission, 2017; Thomas, et al., 2014).  
In addition, physician assistants and nurse practitioners had only recently been added as 
prescribers of BUP and NALT in certified opioid treatment programs (OTPs) or office-based 
practices with MOUDs.  Certified OTPs conformed to the Code of Federal Regulations, CFR 42-
Part 8, governing treatment with MOUD (OFR, 2016).  The required daily visit to specially 
licensed clinics for METH administration also hindered its access.  Another medication, 
naloxone (NAL), μOR antagonist, was FDA approved for treating opioid overdose (SAMHSA, 
2020a).   A combination medication formulated with BUP and NAL was used to decrease the 
potential of BUP being diverted and misused.  
MOUDs had been found to decrease premature morbidity among individuals with OUD 
(Fiellin, et al., 2014; Weiss & Rao, 2017).  Similar positive outcomes had been demonstrated 
specifically with a combination of BUP/NAL.  BUP/NAL maintenance therapy was investigated 
in a Prescription Opioid Addiction Treatment Study (POATS; Weiss & Rao, 2017).  This study 
was the first large-scale study, conducted by the National Drug Abuse Treatment Clinical Trials 
Network, with a sample of patients who were dependent on prescription opioids.  The outcome 
of the study supported the use of BUP/NAL for treatment of prescription opioids dependence.  
Similar success for the use of MOUDs was reported by other investigators (Committee on 
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Substance Use and Prevention, [CSUP], 2016; Fiellin, et al., 2014; Gibson, et al., 2008; Mattick, 
et al., 2009; Mattick, et al., 2014; Sofuoglu, 2018; Thomas, et al., 2014). 
Encouraging Usage of MOUDs. The utilization of MOUDs had been encouraged with 
the passing of legislation in some states (Centers for Disease Control and Prevention [CDC], 
2018b; Davis, et al., 2013).  The Vermont 303 Bill, in conjunction with Section 2703 of the 
Patient Protection and Affordable Care Act (ACA) resulted in a statewide hub-and-spoke 
structured system for OUD treatment (Brooklyn & Sigmon, 2017).  Hubs (typically an OTP) 
were locations where BUP-waivered providers inducted patients with OUD into MOUDs.  
Spokes were step-down clinics where patients were placed after stabilization and for continued 
treatment (ASPE/HHS, 2020; National Academies of Sciences, Engineering, and Medicine 
[NASEM], 2018).  Colorado and Maryland had laws (SB19-008, HB116) which require county 
jails to phase in MOUD treatment programs.  Louisiana and Utah had revised their laws to 
expand the number of practitioners who provided MOUDs.  SAMHSA had certified OTPs to 
utilize pharmacotherapy for people diagnosed with OUD.  To further encourage usage of 
MOUD, most states had office based BUP treatment facilities which serve to increase access to 
MOUD (NSDUH, 2017a; SAMHSA, 2018c). 
Barriers to Treatment 
Despite actions taken to encourage usage of MOUDs, barriers existed that hindered 
access to these medications (Abraham, et al., 2017; Alderks, 2017; KFF, 2019; The President’s 
Commission on Combating Drug Addiction and the Opioid Crisis [The President’s Commission, 
2017]).  Barriers had resulted in a lower prevalence of MOUDs in rural (vs metropolitan) areas 
(The President’s Commission, 2017).  In 2016, 55% of rural counties did not have a SUD 
treatment facility compared to national figures which showed 38% of all U.S. counties (N = 
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3,141) did not have a SUD treatment facility.  Furthermore, 85% of all U.S. counties did not 
have an OTP that provided MOUDs.   
Apart from the scarcity of MOUD facilities in rural areas, the availability of qualified 
physicians with Drug Enforcement Administration (DEA) waivers to administer BUP had been a 
hinderance to treatment utilization in rural areas (MACPAC, 2018; The President’s Commission, 
2017).  Waivered qualified physicians prescribed BUP from office-based practices, or at 
substance abuse treatment facilities.  However, the number of patients to which a waivered 
physician could prescribe BUP, was limited to 100, with further expansion to 275 patients after a 
year (Alderks, 2017; Holly, et al., 2018; The President’s Commission, 2017; SAMHSA, 2020b).  
In 2016, 47% of U.S. counties did not have a DEA-waivered physician (The President’s 
Commission, 2017), with more than half of the physicians in rural areas having a 30-patient 
waiver and not treating any patients.  Other healthcare providers (nurse practitioners, clinical 
nurse specialist, certified registered nurse anesthetists, certified nurse midwives) had been added 
to the list of eligible BUP providers in the office setting, but only until 2023 (SAMHSA, 2020b).   
Barriers had also been created by Centers for Medicare and Medicaid Services (CMS) 
coverage policies concerning SUDs (Barry, 2010; MACPAC, 2018; The President’s 
Commission, 2017).  One specific example related to barriers created by the CMS Institution of 
Mental Diseases (IMD) exclusion, in effect since the inception of Medicaid in 1965.  The IMD 
exception prohibited payment to IMD facilities for diagnosing, treating, or caring for persons 
with mental diseases, which included substance use disorders (SUDs).  Despite this setback, 
most states Medicaid programs offered SUD services, however, coverage gaps (residential 
treatment) existed.  Some states were also not applying for Medicaid Section 1115 demonstration 
waivers, introduced to pay for short-term stay of adults in IMD settings (MACPAC, nd). As of 
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April 2018, only 12 states had participated to pay for full clinical SUD treatment services (CMS, 
nd; MACPAC, 2018).  These services included MOUDs, outpatient and residential treatment for 
SUD.   
The 2010 ACA interceded to change these conditions by providing greater access to 
substance use treatment through coverage expansions and establishment of requirements for 
coverage of SUD treatments in private and public insurance plans (ACA, 2010).  Other barriers 
were unaffordable copayments and limitations in annual SUD treatment visits stipulated in 
coverage policies. 
The Response to Opioid Use Disorder 
The ACA expanded Medicaid, creating stipulations that were beneficial for substance use 
treatment (the mandate for coverage under parental insurance and coverage for preexisting 
conditions like prior SUD treatment; Abraham, et al., 2017; ACA, 2010).  A notable downside of 
the ACA, however, was that there were no stipulations on the type of SUD treatment services 
which should be provided (Abraham, et al., 2017).  As such, states had the leeway in the range of 
SUD treatment services offered to individuals with OUD and in determining whether to adopt 
Medicaid expansion (Abraham, et al., 2017).  Fourteen states had not adopted Medicaid 
expansion (KFF, 2019).  A leading national society on addiction medicine, the American Society 
of Addiction Medicine (ASAM) outlined guidelines and called for insurance companies to 
provide a range of treatment services (MOUDs, residential and outpatient treatment, 
detoxification, recovery and support services) to meet the needs of individuals with OUD 
(ASAM, 2016; MACPAC, 2018).   
Other federal guidelines were in place to support MOUD usage and to lessen substance 
use treatment barriers.  The Substance Use Disorder Prevention that Promotes Opioid Recovery 
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and Treatment for Patients and Communities (SUPPORT) Act of 2018, increased the availability 
of MOUD providers, by allowing varied healthcare providers to prescribe BUP in office-based 
settings (SAMHSA, 2020b).  The Act also created a new state plan option to allow states to pay 
for care for Medicaid beneficiaries with at least one SUD in certain IMDs (MACPAC, 2018).  
In addition, the 2015 Federal Guidelines for Opioid Treatment Programs supported 
accrediting organizations in the development of accreditation standards. These guidelines 
provide OTPs with information on how programs can achieve and maintain compliance with 
federal regulations by delivering patient-centered care that was integrated and focused on 
recovery-oriented standards for substance use treatment.  The Comprehensive Addiction and 
Recovery Act (CARA) of 2016 provided for the awarding of grants to address the prescription 
opioid abuse, the heroin use crisis, and for other purposes (preventing addiction related to youth 
sports injuries, improving access to overdose treatment, National Institute of Health (NIH) opioid 
research, first responder training, prescription drug take back expansion, MOUD for recovery 
from addiction; Congress.gov [2016]). 
It was evident that the OUD responses were inefficient in providing adequate opioid 
treatment facilities, sufficient qualified healthcare providers to administer MOUDs in rural areas, 
limited annual OUD treatment visits stipulated in insurance plans, and appropriate CMS 
coverage policies and payment options for OUD treatment.  Other barriers which affected 
treatment utilization may have existed.  These undetermined barriers for young adults with OUD 
in the U.S. may be found by applying the propositions of ABM. 
Prior studies examined treatment utilization for SUD in the various contexts.  In a 
statewide study, Liebling and colleagues (2016), compared young adults (18-29 years) who had 
enrolled in substance use treatment without facing barriers, young adults who attempted to enroll 
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but faced barriers and young adults who attempted to enroll but were unsuccessful.  Barriers 
were also examined among Latino persons with SUDs (Pinedo, et al., 2018).  The trends in 
treatment utilization, correlates of treatment utilization, and treatment types and settings among 
adolescent with and without SUD were examined by Haughwout and colleagues (2016).  Studies 
also addressed treatment for SUDs, mental health comorbidities, perceived need, and barriers to 
care (Novak, et al., 2019; Rodriguez-Sejias, 2017).  The involvement of the criminal justice 
system in relation to treatment use for co-occurring disorders (mental health and/or SUD) was 
reported by Belenko and colleagues (2013) and Nam and colleagues (2016).  In cross-sectional 
studies, correlates of treatment among various population groups with OUD were examined 
(Romo, et al., 2018; Wu, et al., 2011, 2017).  Insurance coverage status, post ACA, as a correlate 
of treatment utilization was also addressed (Saloner, et al., 2017; Young-Wolff, et al., 2017).  
Correlates like, concurrent substance use, sexual orientation, and insurance were the focus in 
other studies (Ali, et al., 2015, 2017; McCabe, et al., 2013; Saloner, et al., 2017).  Hadland and 
colleagues (2018), in a case series examined stigma as a barrier to SUD treatment among young 
adults. 
A gap existed in literature that focused on treatment utilization as it applied to young 
adults with OUD in the U.S.  The association of multi-dimensional population characteristics 
(demographics, social, personal/family resources, and community resources) with treatment 
utilization among young adults with OUD in the U.S. was not found. 
Study Purpose 
The primary purpose of this study was to address this gap in literature which focused on 
treatment utilization among young adults with OUD in the U.S.  The association of multi-
dimensional population characteristics with treatment utilization among young adults with OUD 
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in the U.S. was not found.  The study was timely for various reasons, among which were, the 
urgency posed by the high prevalence of opioid misuse among the young adult population, the 
high opioid-related mortality rates, and the disparity between treatment needs and treatment 
utilization for OUD among young adults in the U.S. (Bose, et al.,2017; Lipari, et al., 2016). 
Further, the results of this study may provide valuable knowledge related to the 
development of effective strategies to improve access to treatment and recovery support services.  
The results may also enhance treatment engagement and utilization in young adults with OUD in 
the U.S.  Future studies that investigate treatment utilization for SUDs (including OUDs) may 
also benefit from this study’s findings.  
This study sought to associate a broad array of population characteristics with treatment 
utilization among young adults with OUD in the U.S.  Characteristics found to be significant in 
the data analysis may be modifiable.  Similarly, the identification of significant characteristics 
that were non-modifiable was important.  Modifiable and non-modifiable characteristics may 
provide important evidence in the development or enhancement of strategies to encourage 
treatment utilization among young adults with OUD in the U.S.  In the absence of such scientific 
evidence, it may be challenging to develop new treatment strategies or enhance existing ones, 
thereby allowing the opioid health crisis to persist.  Consequently, young adults in the U.S. may 
likely continue to be affected by OUD.  The long-term goal of this research was to add to a 
scientific knowledge base to inform actions to address OUD among young adults in the U.S. 
Theoretical Framework 
The expanded version of the ABM (Figure 1) incorporated characteristics relevant to a 
traditional and/or a vulnerable population and was used to guide the study.  The ABM defined 
vulnerable populations as those who were at greater risk for poor health, experience disparities in 
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life expectancy and morbidity or had limited access to and use of healthcare services 
(Gelberg, et al., 2000).  The vulnerable population was also described as consisting of 
individuals who used drugs. 
The ABM proposed various population characteristics in the traditional and vulnerable 
domains which may be associated with treatment utilization.  The model suggested that treatment 
utilization was a function of a predisposition by people to use treatment services, factors that 
enable or impede such use, and people's need for care (Gelberg, et al., 2000).  The population 
characteristics were therefore categorized as predisposing, enabling or needs based (Aday & 
Andersen, 1974; Andersen, 1968, 2008; Gelberg, et al., 2000).  Further, the ABM recognized 
that individuals in the traditional/vulnerable domains had their own personal practices like self-
care, exercise, and diet.  Health services were posited to be used in the traditional domain, but 
not in the vulnerable domain.  Further, the maintenance and improvement of individuals’ health 
status (based on their own perceptions or an evaluated health status), including satisfaction with 
care, were the explicit outcomes.  Outcomes would then influence subsequent predisposition, 
enabling resources, need, and health behaviors. 
Considering the propositions of the framework, the proposal was that treatment 
utilization among young adults with OUD was associated with the ABM’s predisposing, 
enabling, and needs characteristics in the traditional and/or vulnerable domains.  To develop 
scientific knowledge of treatment utilization among young adults with OUD in the U.S., a 
secondary analysis of a subset of the ABM characteristics which be associated with ABM 
characteristics was performed. 
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Research Question and Hypotheses 
The literature suggested that treatment utilization for OUD and other SUDs among 
adolescents and adults older greater than 25 years was associated with various social and 
personal/family characteristics (education, income, employment status, insurance coverage, 
comorbidities, co-occurring disorders, presence of mental health illness, perceived need, sexual 
orientation, arrest history, abuse of other substances), community resources or perceived health.  
These characteristics were considered as predisposing, enabling or need characteristics in the 
ABM (Ali, et al., 2015, 2017; Belenko, et al., 2013; Gelberg, et al.,2000; Hadland, et al., 2018; 
Haughwout, et al., 2016; Liebling, et al., 2016; McCabe, et al., 2013; Nam, et al., 2016; Novak, 
et al., 2019; Pinedo, et al., 2018; Rodriuez-Sejias, 2017; Romo, et al., 2018; Saloner, et al., 2017; 
Wu, 2011; Wu, et al., 2016; Young-Wolff, et al., 2017).  Covariates examined in prior treatment 
utilization studies demonstrated the association of treatment utilization with a subset of the ABM 
characteristics among adolescent or among adults.  The outcomes of these prior treatment 
utilization studies were not generalizable to the young adult population with similar or additional 
population characteristics.  Further, treatment utilization among young adults with OUD was 
understudied.  Therefore, the research question for this study was: What are the predisposing, 
enabling, and needs characteristics as posited in the Andersen Behavioral Model that are 
significantly associated with treatment utilization among young adults with opioid use disorder 
in the United States?   
Hypotheses 
 Hypothesis One.  One or more prior studies found that the individual more likely to 
utilize OUD treatment was an adult, non-Hispanic white female, with less than a high school 
education and not in the labor force (Hadland, et al., 2018; Haughwout, et al., 2016; Liebling, 
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et al., 2016; Pinedo, et al., 2018; Romo, et al., 2018; Wu, et al., 2011, 2016).  Not in the labor 
force was interpreted as being disabled, keeping house full-time, in school/training, retired, or 
not having a job for some other reason. The likelihood of treatment utilization was also reported 
as positively associated to parent communication, household size, arrest history, and non-
heterosexual.  The consensus in reports was that in the presence of co-morbidities or co-
occurring SUDs, treatment utilization for OUD increased.  A longitudinal study which explored 
treatment utilization for SUD among homeless youth (12-24 years), utilizing SAMHSA national 
treatment data for the years 1992-2017, found that homeless youths had higher odds to self-refer 
to treatment compared to housed youths (Green, et al., 2020).  Determining whether perceived 
need translated into higher treatment for OUD showed mixed results (Haughwout, et al., 2016; 
Romo, et al., 2018; Wu, et. al., 2011).  In Romo and colleagues’ (2018) study, more recent data 
(2010-2014) was used for analysis and included individuals ≥ 18 years (within which the young 
adult falls).  Their findings on perceived need supported the argument that a lack of perceived 
need of treatment resulted in reduced treatment utilization.  
Therefore, it was hypothesized that among young adults with OUD in the U.S., the 
predisposing characteristics (older age, female gender [gender was described as male or female 
by the NSDUH], never married, non-veteran/military status, perceive need of treatment, non-
Hispanic White race/ethnicity, having less than a high school education, not part of the labor 
force, parent communication, household size, non-heterosexual, homelessness, arrest history, 
presence of mental illness, existing comorbidities, co-occurring SUDs) are positively associated 
with treatment utilization. 
Hypothesis Two.   It was difficult to determine based on evidence whether having 
insurance translated into higher treatment for OUD.  Haughwout and colleagues (2016), 
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Liebling and colleagues (2016), Romo and colleagues (2018) found a negative association with 
insurance coverage and SUD treatment among adolescents and adults.  Wu and colleagues 
(2016) found an inverse association.  Intuitively, one may assume that having insurance should 
provide more access to SUD treatment resulting in a positive association with treatment 
utilization and insurance.  A positive association with SUD treatment utilization was evidenced 
among adults having a high income, (Haughwout, et al., 2016; Romo, et al., 2018; Wu, et al., 
2011; Wu, et al., 2016).  Adults receiving public assistance (defined as a program other than 
Medicaid that pays for the last treatment one received, even if it paid only part of the cost) had a 
positive likelihood of obtaining substance use treatment for OUD.  Living in a large 
metropolitan area also increased treatment utilization, as confirmed by Wu and colleagues 
(2011, 2016) and by Romo and colleagues (2018).   
Therefore, it was hypothesized that among young adults with OUD in the U.S., the 
enabling characteristics high income, having insurance coverage, residing in a large 
metropolitan area, and being on one or more public assistance program(s) are positively 
associated with treatment utilization.   
Hypothesis Three.  Study findings by Romo and colleagues (2018) found that among 
adults ≥ 18 years, good health condition had a positive association with treatment utilization.  
Intuitively, one may assume that unless one’s health condition was poor, this finding may be 
reproduced.   
Therefore, it was hypothesized that among young adults with OUD in the U.S., the needs 
characteristic, self-reported health condition was positively associated with treatment utilization.  
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Hypothesis Four.   
Studies that examined treatment utilization found a negative association with mental 
illness and stigma (Ali, 2015, 2017; Hadland, et al., 2018; Novak, et al., 2019; 
Rodriguez-Sejias, et al., 2017; Romo, et al., 2018; Wu, et al., 2011).  These studies utilized 
samples comprised of adolescents or adults.   
As young adults are a subset of the adult population, it was hypothesized that among 
young adults with OUD in the U.S., the predisposing characteristics mental illness and the 
enabling characteristic, stigma are negatively associated with treatment utilization.   
The variables in these hypotheses were established by the propositions in the ABM.  A 
subset of the proposed population characteristics in the ABM were selected to serve as 
covariates.  These covariates posited to associate with treatment utilization were categorized as 
demographics, health beliefs, social structure, sexual orientation, childhood characteristics, 
enabling characteristics (personal/family resources, community resources), and needs 
characteristics (perceived health).  The outcome variable for this study was treatment utilization, 
which was based on the receipt of treatment in the past year.  
Summary 
 The increasing SUD-related mortality rates, particularly due to OUDs and the disparity 
between treatment need and treatment receipt for SUDs was alarming.  Young adults had higher 
SUD treatment needs.  OUD, a subset of SUDs, heroin use disorder may lead to serious health 
complications and even death.  MOUDs were available and their use were encouraged, however 
existing barriers discouraged or precluded treatment altogether.  Treatment for OUD had been 
reported to reduce mortality.  Young adults with OUD need treatment.  This study associated 
demographics, social and personal/family characteristics posited in the ABM, with treatment 
TREATMENT UTILIZATION FOR OPIOID USE DISORDER   
22 
utilization among young adults with OUD in the U.S.  The study was important, timely and 
necessary to advance scientific knowledge necessary to guide the development of effective 
strategies and to enhance existing strategies to improve treatment engagement and treatment 
utilization among young adults with OUD in the U.S.  
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Chapter 2: Literature Review 
To inform this secondary analysis, a literature search was performed to identify studies 
that focused on treatment utilization among young adults with opioid use disorder (OUD) in the 
U.S.  A database search was conducted of peer-reviewed journals published from 2010 to 2018.  
The year 2010 was selected for multiple reasons.  First, notable events beginning in the 1990s 
were the liberation of laws leading to the deregulation of opioid prescribing for pain management 
(Kolodny, et al., 2015), increase in physician opioid prescribing, quadrupling of prescription 
opioid sales in the years 2000 to 2010 and increased opioid overdose deaths (Sullivan & Howe, 
2013).  By 2017, 191 million opioid prescriptions were dispensed (CDC, 2017b; CDC, 2018a), 
representing a triple increase compared to 1999 (CDC, 2018b).  Non-medical opioid usage, 
unintentional overdose deaths, prescription drugs misuse and dependence disorders saw a 
significant increase (CDC, 2011; Compton & Volkow 2006; Daniulaityte, et. al., 2014; Gilson, 
et al., 2001; Paulozzi & Annest, 2007; Paulozzi, et al., 2006; Paulozzi & Xi, 2008; SAMHSA, 
2010b; Zacny, et al., 2003).  Barriers (lack of health coverage, high cost of treatment and 
unemployment) existed for individuals needing substance use treatment (CBHSQ, 2014).  The 
2010 ACA introduced reforms to the health care system, which were supposed to alleviate these 
barriers and make health insurance coverage more affordable, improve access to health care 
services for SUDs, and eliminate the loss of health insurance due to loss of employment 
(CBHSQ, 2014).  Disparities in treatment use and treatment needs for SUDs, including OUD, 
were still reported in studies for the years 2015 and 2016 (Park-Lee, et al., 2016; 2017).   
Second, a rising prevalence of prescription pain reliever and other opioid misuse and 
dependence disorders were observed in 2010 (CDC, 2011; SAMHSA, 2010b).  Third, the ACA 
allowed states participating in ACA Medicaid expansion to offer SUD services (ACA, 2010).  
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Fourth, in 2010, the rate of illicit drug use, including prescription opioids misuse was higher for 
young adults (21.2%) up from 19.6% in 2008 than for adolescents (10.1%) up from 9.3% in 2008 
and individuals over 25 years old (6.3%) in 2008 (SAMHSA, 2011).  Examining the broad array 
of ABM characteristics that relate to this study’s phenomenon, using 2010 as starting point for 
the literature search seemed appropriate.    
Search Strategy 
CINAHL Complete, MEDLINE, Academic Search Complete, Social Science Full Text 
(H.W. Wilson), PsychINFO, Proquest Dissertations & Theses Global databases, and Google 
Scholar were searched using the keywords “treatment” and “opioid or painkiller” and “abuse or 
misuse”.  These terms were derived from the definition of the term OUD (SAMHSA, 2018b).  
Keywords were further modified to include “treatment or intervention or therapy”, “opioids or 
painkillers”, “abuse or misuse” and “young adults”.  Duplicates were removed from the resulting 
search outcome, titles and abstracts were screened, and inclusion and exclusion criteria applied.  
Excluded were articles in which treatment utilization for OUD was not addressed or the focus 
was on substances with the exclusion of opioids.  Empirical studies show that treatment 
utilization for OUDs was influenced by co-morbidities and other co-occurring SUDs.  A second 
search was conducted using the initial set of databases to include the search terms 
“co-morbidities” and “co-occurring substance use disorders”.  Duplicates were removed, 
title/abstract screening performed, and exclusion criteria applied.  Additional manuscripts that 
focused on co-morbidities, co-occurring SUDs and treatment utilization were retrieved. 
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Summary of the Literature  
Treatment Utilization (Outcome Variable) 
Treatment utilization among adolescents, young adults, and older adults with OUD, in the 
presence of other SUDs, mental illness, and co-morbidities was examined in multiple studies 
(Table 5).  Studies that addressed characteristics defined in the ABM as scant.  Survey estimates 
indicated a high prevalence of SUDs in the U.S.  (Bose, et al., 2017; Park-Lee, et l., 2017).  The 
rate at which individuals utilize SUD treatment, however, was shown to be consistently low 
(Lipari, et al., 2016; Park-Lee, et al., 2017; Bose, et al., 2018).   
Predisposing Characteristics Associated with Treatment Utilization 
Demographics 
 Consistently low SUD treatment utilization had been reported in studies that provided 
descriptive statistics on demographic characteristics (age, gender, and race/ethnicity).   
 Older Age.  Adults > 25 years old used OUD treatment more frequently than young 
adults, young adults used OUD treatment more frequently than adolescents.  These findings were 
reported in studies that investigated correlates to treatment utilization for OUD among 
adolescents, adults and treatment use in the presence of mental illness and SUD among adults 
(Romo, et al., 2018; Saloner & Karthikeyan, 2015; Wu, et al., 2011, 2016). 
 Gender.  More females than males accessed OUD treatment among individuals 
≥ 12 years old, while males with an arrest history tended to have increased SUD treatment 
(Wu, et al., 2011; 2016; Hadland, et al., 2018; Haughwout, et al., 2016).  These findings were 
based on the survey of adolescents in a study by Haugwout and colleagues (2016) and Wu and 
colleagues (2011, 2016) which focused on the past year’s substance use and trends in treatment 
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utilization and in a study by Hadland and colleagues (2018) identifying time trends and 
disparities in receipt of BUP and NALT among youths with OUD in the U.S.  
 Race/ethnicity.  More White than non-White persons used OUD treatment, whereas 
more Hispanic/Latino persons used OUD treatment more than Black persons (Hadland, et al., 
2018; Haughwout, et al., 2016; Liebling, et al., 2016; Pinedo, et al., 2018; Romo, et al., 2018).  
Multiple studies investigated racial/ethnic disparities in the receipt of pharmacotherapy for OUD, 
(Hadland, 2018, Haugwout, et al., 2016, Liebling, et al., 2016, Romo, et al., 2018).  Pinedo and 
colleagues (2018) investigated specialty treatment for SUD among a sample of White, Black, 
and Latino participants with recent SUD.  Latino persons were the only group to be discouraged 
from using services not culturally appropriate (family over individual, respect based on age and 
social position, acknowledgment of social contexts).   





Characteristics Associated with Treatment Utilization for SUD Among Adolescents (12 – 17 years), Young Adults (18- 25 years) and Older Adults Over 25 Years Old 
    Characteristics 
      examined 
Adolescents Young adults ≥ 12 years old ≥ 18 years old 
Older adults over 25 
years old 
Age Being an adolescent 
with an OUD had a 
negative relationship 
with utilizing OUD 
treatment (Wu, et al., 
2011) 
Young adults used opioid 
treatment more than 
adolescents (Wu, et al., 2016) 
̶ Most adults did not use treatment 
for OUD (Romo, et al.,2018; 
Saloner & Karthikeyan, 2015) 
This group used opioid 
treatment more than young 
adults (Romo, et al.,2018) 
Adults in this group used 
opioid treatment more than 
adolescents (Wu, et al., 2016) 
Gender 
More males than 
females used SUD 
treatment, including for 
OUD (Hadland, et al., 
2018; Haughwout, 
et al., 2016; Wu, 
et al., 2011) 
̶ More females than males 
used opioid specific treatment 
(Wu, et al., 2016) 
̶ Younger men used less tobacco 
treatment (Young-Wolff, 2017) 
Marital status ̶ ̶ ̶ Adults with OUD and were never 
married had a higher usage of 
specialty treatment use as 
compared to those who were 
separated/widowed/separated or 




̶ ̶ ̶ ̶ ̶ 
Perceived need Perceived need 
increased SUD 
treatment use among 
adolescents 
(Haughwout, et al., 
2016) 
̶ ̶ Results indicated that increased 
service utilization was associated 
with perceiving a need for 
substance abuse treatment (Ali, 
Teich, & Mutter, 2015).  
When they received treatment, 
they were more likely to receive 
mental health treatment (Ali, 
Teich, & Mutter, 2015).  
Lack of a perceived need for OUD 
treatment decreased treatment use 
(Romo, et al., 2018) 
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    Characteristics 
      examined 
Adolescents Young adults ≥ 12 years old ≥ 18 years old 




Treatment use had a 
negative relationship 
among non-Hispanic 
Black persons, Hispanic 
males, non-Hispanic 
female who had a SUD 
compared to White 
persons (Haughwout, 
et al., 2016) 
Black and Hispanic 
persons used OUD 
treatment less than 
White persons 
(Hadland, 2018; Wu, 
et al., 2011) 
Non-White persons had a 
lesser chance of treatment use 
for OUD (Liebling, et al., 
2016) 
Blacks and Native 
Hawaiian/Pacific Islander, 
and Asian American persons 
particularly underutilized 
opioid-specific treatment 
much less compared to White 
persons (Wu, et al., 2016) 
Hispanic, mixed race, and 
Native American persons 
used opioid specific treatment 
less than White persons (Wu, 
et al., 2016) 
Hispanic adults used OUD 
specialty treatment more than 
Black, and non-Hispanic White 
adults (Romo, et al., 2018) 
Latino persons more than Black 
and White persons underutilized 
specialty treatment for SUDs 
(Pinedo, 2018) 
Latino persons who perceived a 
need for alcohol or drug 
treatment were more likely to 
use mental health treatment 
versus substance abuse 
treatment (Pinedo, 2018) 
Asian and Latino smokers used 
less tobacco treatment (Young-
Wolff, et al., 2017) 
Education ̶ ̶ ̶ Adults with less than a high school 
education used specialty treatment 
more than college graduates 
(Romo, et al., 2018) 
̶ 
    Employment ̶ ̶ ̶ Not being in the labor force and 
having OUD had a positive 
association with specialty 
substance use treatment as 
compared to those employed 
full/part-time or unemployed 




Talking to parents 
increased SUD 
treatment use, including 
OUD treatment use 
(Haughwout, et al., 
2016; Wu, et al., 2011) 
̶ ̶ ̶ ̶ 
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    Characteristics 
      examined 
Adolescents Young adults ≥ 12 years old ≥ 18 years old 
Older adults over 25 
years old 
Household size ̶ ̶ ̶ Household with one individual, 
sought specialty treatment for 
OUD less than household in which 
there were two, three, four or more 




̶ ̶ ̶ ̶ Heterosexual men were more 
likely to report substance abuse 
treatment than were 
heterosexual women (McCabe, 
et al., 2013) 
Homelessness ̶ Young adults (18 - 29 years) 
with OUD and were homeless 
showed decreased treatment 
use for OUD (Liebling, et al., 
2016) 
̶ ̶ ̶ 
Arrest history Males with an arrest 
history increased SUD 
treatment (Haughwout, 
et al., 2016) 
Adolescents with OUD 
and an arrest history 
had a positive 
relationship with 
treatment use (Wu, 
et al., 2011) 
Young adults (18 - 29 years) 
with OUD and had an arrest 
history showed decreased 
treatment use for OUD 
(Liebling, et al., 2016) 
̶ Having an arrest history with OUD 
had a positive association with 
specialty substance use treatment 
(Romo, et al., 2018) 
Adults with an arrest history were 
more likely than those without an 
arrest history to receive mental 
health treatment or substance 
abuse treatment alone. (Nam, 
et al., 2016) 
̶ 
Mental illness ̶ ̶ ̶ Adults with serious mental illness 
used specialty treatment for OUD 
more than those with no mental 
illness or mild mental illness or 
moderate illness (Romo, et al., 
2018) 
In the presence of comorbid 
conditions (mental illness), 
SUD had a negative relationship 
with treatment use, but the 
mental illness had a positive 
relationship with treatment use 
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    Characteristics 
      examined 
Adolescents Young adults ≥ 12 years old ≥ 18 years old 
Older adults over 25 
years old 
(Ali, et al., 2015) 
In the presence of comorbid 
conditions (OUD and mental 
illness), OUD had a negative 
relationship with treatment use. 
but the mental illness had a 
positive relationship with 
treatment use (Novak, et al., 
2019)  
In the presence of OUD and 
serious mental illness, 
treatment use increased for 
both co-occurring conditions 
as opposed to the co-occurring 
conditions OUD and mild 





SUD treatment use had 
a positive relationship 
in the presence of other 
SUDs except alcohol 
use disorder 
(Haughwout, et al., 
2016).   
In the presence of OUD 
and SUD comorbidities, 
treatment use increased 
(Wu, et al., 2011) 
̶ People with alcohol use 
disorder used treatment less 
than people with OUD (Wu, 
et al., 2016) 
Low treatment use with 
severe patterns of OUD and 
SUD comorbidity (Wu, et al., 
2016) 
Having another SUD with OUD 
had a positive association with 
specialty substance use treatment 
(Romo, et al., 2018)  
Treatment for mood/anxiety 
disorder increased in the 
presence of SUDs (Rodriguez-
Sejias, et al., 2017) 
Income Higher income was 
positively associated to 
treatment use (Wu, 
et al., 2016) 
̶ Those with higher income 
used more opioid specific 
treatment (Wu, et al., 2016) 
̶ ̶ 
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SUD treatment use had 
a negative relationship 
with the individual’s 
insurance coverage 
status (Haughwout, 
et al., 2016) 
Adolescents with OUD 
and covered by private 
were less likely to use 
OUD treatment (Wu, 
et al., 2011) 
Insurance was not associated 
with treatment use for OUD.  
Study sample was small and 
the state where study was 
conducted was a Medicaid 
expansion state. (Liebling, 
et al., 2016) 
Those with insurance used 
opioid specific treatment 
more than those with no 
insurance (Wu, et al., 2016) 
People with public insurance 
used OUD treatment more 
than people with private 
insurance (Wu, et al., 2016) 
Lack of insurance decreased 
treatment use for OUD (Romo, 
et al., 2018) 
Adults with OUD and public 
insurance used specialty 
treatment more than people with 
private insurance or no insurance 
(Wu, et al., 2016) 
No significant difference 
(McCabe, et al., 2013) 
The decision to seek treatment 
for substance abuse was 
contingent on insurance and 
having a perceived need.  Those 
who sought treatment from self-
help groups were excluded (Ali, 
et al., 2015) 
Medicaid smokers were more 
likely to use patient tobacco 
treatment to exchange and 
commercial (Young-Wolff, 
et al., 2017) 
Individuals with mental and 
SUDs, in the presence of 
coverage had a negative 
relationship with treatment use 
(Saloner, et al., 2017) 
Residence Adolescents in small 
metropolitan locations 
used OUD treatment 
less than people in large 
metropolitan locations 
(Wu, et al., 2011) 
̶ People in small metropolitan 
locations used OUD 
treatment less than people in 
large metropolitan locations 
(Wu, et al., 2016) 
Residence in a non-metropolitan 
county was negatively associated 
with receiving specialty substance 
use treatment for OUD (Romo, 
et al., 2018) 
̶ 
Stigma Stigma among 
adolescents with OUD 
had a negative 
relationship treatment 
use (Wu, et al., 2011) 
Stigma had a negative 
relationship with SUD 
treatment (Hadland, et al., 
2018) 
̶ ̶ Stigma had a negative 
relationship with SUD treatment 
especially among those with 
private insurance (Ali, et al., 
2017) 
Stigma had a negative 
relationship with opioid use 
disorder treatment (Novak, 
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No difference in SUD 
treatment among those 
with public insurance or 
no insurance 
(Haughwout, et al., 
2016) 
̶ ̶ Adults with OUD and receiving 
public assistance had a positive 
relationship with using treatment 
for OUD (Romo, et al., 2018) 
Persons covered by Medicaid or 
receiving other forms of public 
assistance were more likely to 
receive substance abuse 
treatment than the privately 
insured (Ali, 2015)  
Health condition ̶ ̶ ̶ Individual with good health and 
OUD, used OUD specialty 
treatment more than those with 
excellent/very good or poor/fair 
health (Romo, et al., 2018) 
̶ 
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Perceived Need for Treatment 
Ali and colleagues (2015) had found a high percentage (97%) of adults did not perceive a 
need for treatment and 80% did not receive treatment in the analysis of five years (2008 - 2012) 
of NSDUH data.  The aim of the study was to understand the role health insurance played in 
influencing the use of substance abuse treatment and/or mental health treatment, given there was 
a perceived need for treatment.  Results from their study indicated that increased treatment 
utilization was associated with perceiving a need for substance abuse treatment.  Similar results 
were found in a nationally representative sample of adults with OUD, in a cross-sectional study 
based on the years 2010 to 2014 (Romo, et al., 2018).  Romo and colleagues examined correlates 
of treatment utilization among adults.  Haughwout and colleagues (2016) found a positive 
relationship between perceived need and SUD treatment utilization among adolescents in a 
pooling of NSDUH data for the years 2002 - 2013.  In these studies, the response to the question: 
“during the past 12 months, did you make an effort to get treatment or counseling” for drug use, 
determined perceived need for treatment.  
Education, Employment, Household Size, Arrest History, Homelessness, Concurrent 
Substance Use, Comorbidities 
Increases in SUD treatment among adults were associated with having less than a high 
school education and not being in the labor force or unemployed (Haughwout, et al., 2016; 
Romo, et al., 2018; Wu, et al., 2011; Wu, et al., 2016).  Unemployed meant on layoff or looking 
for work.  Those who lived alone were reported to have decreased SUD treatment utilization.  
Employed persons had treatment limitations in their employee-sponsored insurance plans, and 
faced stigma, while the unemployed were covered by Medicaid and other state plans or were part 
of the criminal justice system allowing for more access to SUD treatment (Ali, et. al., 2017; 




Belenko, et al., 2013; Bureau of Justice Statistics, 2020; Hadland, et al., 2018; IRS, 2020; 
National Institute of Correction 2017, n.d.).  OUD treatment among individuals ≥ 12 years old 
had a positive relationship with arrest history (Haughwout, 2016; Liebling, et al., 2016; Romo, 
et al., 2018; Wu, et al., 2011).  Additionally, homelessness had a negative associated with SUD 
treatment (Ali, et al., 2017; Hadland, et al., 2018; Liebling, 2016; Novak, et al., 2019).  Low rate 
of SUD treatment utilization was associated with concurrent use of substances (Wu, et al., 2016).  
Rodriguez-Sejias and colleagues (2017) found a positive association with SUD treatment 
utilization and comorbidities among a nationally representative sample of adults.  Other studies 
showed similar associations with comorbidities and OUD/SUD treatment utilization, among 
adolescents and adults (Haughwout, 2016; Romo, et al., 2018). 
Mental Illness 
The ABM suggested that mental illness, a predisposing characteristic, played a role in 
treatment utilization.  The literature found, reported that adults with OUDs and co-occurring 
mental illness, sought treatment for mental illness rather than for OUD (Ali, et al., 2015; Novak, 
et al., 2019).  Similarly, Rodriguez-Sejias and colleagues’ (2017) study based on a nationally 
representative sample of adults, focused on individual mental disorders and found that treatment 
utilization for SUD decreased, in the presence of mood and anxiety disorders. 
Enabling Characteristics Associated with Treatment Utilization 
Insurance 
 Insurance was an enabling characteristic posited in the ABM to associate with treatment 
utilization.  Among adolescents in the years 2002 - 2013, Haughwout and colleagues (2016) 
reported a negative relationship between insurance coverage status and SUD treatment.  The 
same negative association was observed among a small sample of young adults (18 - 29 years) in 
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a Medicaid expansion state (Liebling, et al., 2016) and among adults (in the years 2010 - 2014) 
with OUD (Romo, et al., 2018).  Wu and colleagues (2016), however, found an inverse 
association, in the analysis of NSDUH data for the years 2005 - 2013.  Individuals ≥ 12 years 
with public insurance coverage used OUD treatment more than young adults with no insurance.  
Individuals having public insurance were more likely to use OUD treatment than individuals 
with private insurance (Ali, et al., 2017; Wu, et al., 2016).  Further, Wu and colleagues (2016) 
found that having Medicaid or private insurance was associated with a greater likelihood of 
receiving SUD treatment, but only when the individual perceived a need for it, compared to 
being uninsured and not perceiving a need for treatment.  The multiple analysis of the potential 
impact of insurance coverage on treatment utilization posed uncertainties in determining whether 
having insurance coverage translated into an increased or decreased rate of SUD treatment. 
Insurance coverage concerns brought about by The Patient Protection and Affordable 
Care Act (PPACA) (which was fully implemented in 2014).  The insurance mandate in the 
PPACA was expected to substantially increase SUD treatment utilization (Abraham, et al., 
2017).  Forty million uninsured individuals were expected to gain access to an array of health 
services with congressional approval of the ACA (Garfield, et al., 2019).  In 2017, however, 
27.4 million people remained without insurance coverage.  At that time, approximately 18.7 
million individuals had a SUD, 46.6 million had a mental health disorder, and 8.5 million had 
both (McCance-Katz, 2018).   
Public Assistance 
Increases in SUD treatment associated with receiving public assistance was reported in 
studies that examined factors associated with the past year’s substance use treatment, among 




adolescents, adults, and individuals ≥ 12 years old (Haughwout, et al., 2016; Romo, et al., 2018; 
Wu, et al., 2011; Wu, et al., 2016).   
Stigma 
Stigma was defined as both a social and psychosocial process initiated by non-
marginalized individuals to create exclusion (Ahern, et al., 2007).  Marginalized individuals 
perceived their exclusion as a negative stereotype and internalized their perceptions.  Research 
suggested that stigmatization may result in attempts to hide drug use.  Ali and colleagues (2017) 
definition of stigma “as not receiving treatment because neighbors would have a negative 
opinion, or the individual did not want others to know, or thought it would have a negative effect 
on his or her job” exemplified the actions taken by marginalized individuals to evade being 
stigmatized.  Findings from studies that investigated stigma, showed an adverse association with 
SUD treatment among young adults who used prescription painkillers non-medically (Ali, et al., 
2017; Liebling, et al., 2016; Novak, et al., 2019). 
Needs Characteristics Associated with Treatment Utilization 
Self-Reported Health Conditions 
Health condition was described as a population need characteristic which played a role in 
treatment utilization.  This population characteristic relating to an individual’s self-reported 
health was minimally addressed in studies found.  A single study reported that in the adult 
population, individuals with good health and having OUD were more likely to use OUD 
specialty treatment more than those with excellent or poor health (Romo, et al., 2018). 
Treatment Utilization Among Adolescents with OUD 
 Scientific knowledge reported on OUD treatment utilization among adolescents was 
important for the current analysis.  Data analyzed for the years 2016-2017, showed that 3.1% of 




adolescents in the U.S. misused opioids compared to 7.3% of young adults (Bose, et al., 2017).  
Even though rates are lower for the adolescent group than the young adult group, adolescents 
eventually became young adults and had new and different characteristics that influenced their 
utilization of OUD treatment.  Conflicting results were shown by Wu, et al., 2011 and 
Haughwout, et al. 2016 relating to treatment utilization and perceived need among adolescents.  
Wu and colleagues (2011) reported that adolescents were less likely to perceive a need for OUD 
treatment.  Haughwout and colleagues (2016) found that perceived need increased SUD 
treatment, as did parent communication about the dangers of substance use. 
Comorbidities and Other Substance Use Associated with Treatment Utilization 
Comorbidities and concurrent substance use have contributed to increased OUD 
treatment in adolescents (Haughwout, et al., 2016; Wu, et al., 2011).  The inverse association 
was shown in Wu and colleagues’ (2016) study among adults.  Wu, and colleagues (2011) 
examined adolescents in a longitudinal study.  Haughwout, et al., 2016 study had a larger 
longitudinal set.  Wu et al. (2016) findings were also derived in longitudinal findings.  Additional 
associations found to exist between other predisposing, enabling and needs characteristics among 
young adults, older adults and adolescents are detailed in Table 5. 
Summary 
 Previous studies provided evidence that demographics, health beliefs, social structure, 
sexual orientation, childhood characteristics, enabling characteristics (personal/family resources, 
community resources), and needs characteristics (perceived health) were associated positively or 
negatively with SUD treatment utilization.  The focus of these prior studies was on the 
adolescent and the adult (> 25 years old) population.  OUD was minimally addressed.  
Extrapolating knowledge from prior studies which can be translated to young adults’ treatment 




utilization for OUD was difficult.  Further, studies synthesized, lacked, or marginally produced 
scientific knowledge on the association of the ABM broad array of population characteristics to 
treatment utilization among young adults with OUD in the U.S.  Young adults have a greater 
need for OUD treatment based on their high prevalence of OUD compared to adults > 25 years.  
For these various reasons, the need for the current analysis was necessary.  




Chapter 3: Methods 
Research Design 
The study design was a secondary analysis of a subset of data extracted from the primary 
dataset: The 2017 NSDUH (SAMHDA, 2017) dataset. 
Primary Study Data Source 
The 2017 NSDUH dataset (SAMHDA, 2017) was the U.S.’s primary source of national 
estimates on the use of alcohol and illicit drugs, SUDs, behavioral/mental health and substance 
use treatment in 2017 (Bose, et al., 2017).  SAMHSA used DSM-IV in determining survey 
participants’ SUD status (Bose, et al., 2017).  The dataset contained data pertinent to ABM 
population characteristics (predisposing, enabling and needs characteristics), which were posited 
to associate to treatment utilization.  These data were used to examine the research question for 
this study:  What are the predisposing, enabling, and needs characteristics as posited in the 
Andersen Behavioral Model that are significantly associated with treatment utilization among 
young adults with opioid use disorder in the United States?   
Participants in the 2017 NSDUH included U.S. civilians who were noninstitutionalized, 
and residing within the U.S. (Bose, et al., 2017).  Participants were residents of households 
(including civilians living in housing on military bases), or individuals in non-institutional group 
quarters (shelters, boarding houses, college dormitories, migratory workers’ camps, halfway 
houses), or homeless individuals with no permanent address but housed in shelters or single 
rooms in hotels.  Forty-eight contiguous states, Hawaii, and Alaska were represented, with a 
small proportion (approximately 3%) of the U.S. population excluded.  The excluded were 
members of the active-duty military, individuals in institutional group quarters (long-term care 
hospitals, institutional group quarters like prisons/jails, nursing homes, mental institutions), and 




homeless individuals with no permanent address and not housed in a shelter).  Participants were 
derived from 6,000 area segments that vary in size according to the state.   
Primary Study Data Collection  
The procedure used to select participants for the 2017 NSDUH involved visits by field 
interviewers (FI) to sampled addresses (NSDUH, 2017b).  In 2017, the quarterly design of the 
survey required FIs to visit dwelling units (DUs) at each sampled address, to determine the 
eligibility of the DU, to list individuals at the DU’s address, to select the sample of individuals to 
be interviewed (if any), and to conduct interviews.  A staff of approximately 650 FIs were 
maintained for screening of possible participants.  During the screening interview, FIs obtained 
information on other DUs on the property.  Any missing DU on the original DU list was included 
in the sample. 
The FIs used handheld computers to record results of the DU screening process and to 
select the sample of for interviewing (NSDUH, 2017b).  The handheld computer had computing 
abilities and utilized parameters specified for each area segment, in combination with a random 
number to determine sampled addresses.  Each quarter, small reserve samples were held back so 
that the assigned sample size could be adjusted, as needed, during the data collection process.  
During quarterly intervals, the survey’s progress was monitored by the state. 
A total of 68,032 computer-aided interviews (CAIs) were obtained for the 2017 NSDUH 
(NSDUH, 2017b).  The weighted screening response rate was 75.08% and the weighted 
interview response rate for the CAIs was 67.12%.  Throughout the screening process, anonymity 
and privacy of participants were protected by separating identifying information from survey 
responses.  Compliance with federal laws relating to privacy was made known to participants.  
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Additionally, privacy concerns, project descriptions, and frequently asked question were made 
available on an NSDUH public information website. 
The survey data collection tool utilized in the 2017 NSDUH, was an audio computer-
assisted self-interviewing (ACASI) system.  This tool provided participants with a highly private 
and confidential environment to answer questions.  This environment was created to increase the 
level of honest reporting of drug use behaviors.  Survey answers to sensitive questions were 
gathered through the ACASI system.  During the ACASI portions of the interview, participants 
listened to prerecorded questions through headphones and entered responses directly into a 
computer without FIs having knowledge of answers.  At the conclusion of the ACASI section, 
the interview returned to the computer-assisted personal interviewing mode with the FI asking 
the participants questions and entering the responses into the laptop.  Each participant who 
completed a full interview was compensated $30 in cash. 
Primary Study Dataset Validation Procedures   
The 2017 NSDUH questionnaire was used to collect cross-sectional data.  In prior data 
collection surveys, the possibility of participants misunderstanding survey questions and the 
effects of field were recognized as possible problems with data collection (SAMHSA, 2010a).  
To address these problems, the reliability and consistency of past and current surveys were 
tested in reliability studies involving re-interviewing of the survey’s participants.  In the 
reliability studies, the same survey was used with a subset of participants.  The aim was to 
obtain a direct measure of the response variance, to evaluate the quality of the surveys and to 
document the findings of the evaluation, to assist users of the survey, in their interpretation and 
uses of findings from the surveys.  Questions that did not score high on the studies’ reliability 
measures were identified, tested, and improved. 




Current Study (Secondary Analysis) Data Source  
A subset of the primary data source, the 2017 NSDUH dataset (SAMHDA, 2017), served as 
the data source for this study.  The inclusion criterion for selecting the study’s sample was all 
survey participants in the age group 18 - 25 years old AND with a diagnosis of OUD.  The 
exclusion criteria for sample selection were all survey participants less than 18 years old or 
greater than 25 years old or in the 18 - 25 years old age groups without a diagnosis of OUD. 
Participants’ OUD status was contained in the dataset as the dichotomous variable, 
OPINMYR.  A participant’s OUD status was determined by SAMHSA using the DSM-IV 
criteria (Table 1).  OUD was attributed to the use of heroin and/or misuse of prescription 
opioids in the past year.  The subset of data extracted for this study totaled 1,021 survey 
participants from the primary data source.  
Variable Measurement 
The variables in the study were organized according to the population characteristics in 
the traditional and vulnerable domains described in ABM.  The model posited that treatment 
utilization (a health behavior) was associated with an individual’s predisposing characteristics 
(demographics, health beliefs, social structure, sexual orientation, childhood characteristics), 
enabling characteristics (personal/family resources, community resources), and needs 
characteristics (perceived health; Gelberg, et al., 2000).  
This study examined selected predisposing, enabling, and need characteristics which may 
be associated with treatment utilization (Table 6).   
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Table 6  
List of the predisposing, enabling, and need characteristics 
Predisposing Enabling Need 
Demographics Personal/Family Resources Perceived Health 
Age Insurance Self-reported health condition 
Gender Income 
Marital status Parent communication 
Veteran/Military status Public assistance program 
Health Benefits Community Resources 
Perceived need Residence location 










Other substance use 
Predisposing Characteristics.  Predisposing characteristics posited in the traditional 
domain of the ABM and extracted from the 2017 NSDUH dataset included (Table 7): age, 
gender, marital status, veteran status, perceived need, ethnicity, education, employment, and 
household size.  In the vulnerable domain of the ABM, sexual orientation, homelessness, arrest 
history, mental illness, and other substance use were extracted.   
Enabling Characteristics.  Enabling characteristics examined in this study: insurance, 
income, parent communication, residence, stigma, and participation in public assistance 
program.  Details of each variable are provided in Table 7. 





Data Type and Imputed/Recoded Status of Covariates Analyzed in This Study 
Covariates Type Imputed / 
Recoded 
NSDUH selected data to measure the study’s variables 
Demographics 
Age Categorical No/Yes The age in years of the survey’s participants (age values: 18, 19, 20, 21, 22, 23, 24, 25 years). 
Gender Dichotomous No/No Male or female. 
Marital status Dichotomous Yes/Yes Married or not married (widowed, divorced, separated, never married). 
Veteran/Military 
status 
Dichotomous No/No Reserved or retired/separated/retired from active duty. 
Health benefits 
Perceived need Dichotomous Yes/Yes Perceived need was obtained from the question: during the past 12 months, did you need treatment or 
counseling for your use of prescription pain relievers? 
Social structure 
Race/ethnicity Categorical Yes/Yes Race/ethnicity was obtained based on seven categories: non-Hispanic White, non-Hispanic Black/African 
American, non-Hispanic Native American/Alaska Native, non-Hispanic Native Hawaiian/Pacific Islander, 
non-Hispanic Asian, non-Hispanic mixed race, and Hispanic. 
Education Categorical Yes/Yes Education level was provided from the following choices: grade levels 5 through 10, grade 11/12 completed 
with no diploma, high school completed with GED, some college credits (no degree), associate degree, or 
college graduate/higher. 
Employment Categorical Yes/Yes Employment categories: employed full time, employed part time, unemployed, other (not in the labor force). 
Household size Categorical Yes/Yes Household size was provided from the following choices: 1, 2, 3, 4, 5, 6 or more. 
Sexual orientation Categorical No/No Sexual orientation was provided from the following choices: heterosexual/straight, lesbian/gay, or bisexual. 
Community Resources 
characteristics Resident location Categorical Yes/Yes Resident location was classified as large metropolitan, small metropolitan, or non-metropolitan. 
Stigma Dichotomous No/No Values to the following questions determined stigma: (a) did not get treatment because treatment might cause 
neighbors to have negative opinion? (b) Did not get treatment because treatment might have negative effect on 
job? (c) Did not get treatment because did not want others to know?) 
Childhood 
characteristicsHomelessness n/a n/a Variable not made available in the 2017 NSDUH dataset 
Arrest history Dichotomous No/No Arrest history refers to being taken into custody, processed by the police or a court representative, even if 
released. Mental illness Categorical Yes/Yes Mental illness was any mental illness characterized as absent, serious, moderate, or mild.
Other substance 
use
Dichotomous Yes/Yes Other substance abuse in the 2017 NSDUH dataset was based on DSM-IV criteria. 





Data Type and Imputed/Recoded Status of Covariates Analyzed in This Study 
Covariates Type Imputed / 
Recoded 
NSDUH selected data to measure the study’s variables 
Personal/family 
resources 
Insurance coverage Categorical No/Yes Insurance coverage was defined as private / public (Medicaid) or insurance from special providers for the 




Categorical No/No Parent communication is described as talking to at least one parent about the dangers of tobacco, alcohol, or drug 













Dichotomous No/Yes Treatment utilization was based on a survey participant’s receipt of treatment in the past year. 




Need Characteristics. The need characteristic in the vulnerable domain of the ABM, 
extracted from the 2017 NSDUH dataset and examined in this study was the self-reported health 
condition of the survey participant.  
Special Measurement Cases.  The variables perceived need and stigma were measured 
by participants’ responses to specific survey questions.  The use of these questions to analyze 
perceived need and stigma was consistent with other studies and/or based on recommendations 
from the 2017 NSDUH: Methodological Summary and Definitions (MSD; Ali, et al., 2015; 
Romo, et al., 2018; SAMHSA, 2018b; Stringer & Baker, 2018).  The MSD was a report that 
summarized methods and other supporting information that were relevant to estimates of 
substance use. 
The following 2017 NSDUH questions measured perceived need: During the past 12 
months, did you need treatment or counseling for your use of prescription pain relievers? 
During the past 12 months, did you need treatment or counseling for your use of heroin?   
Stigma was analyzed in this study by the following 2017 NSDUH questions: Did not get 
treatment because treatment might cause neighbors to have negative opinion? Did not get 
treatment because treatment might have negative effect on job? Did not get treatment because 
did not want others to know?   
Treatment Utilization.  Treatment utilization, the outcome variable in this study, was 
based on a survey participant’s receipt of treatment in the past year.  In the 2017 NSDUH, the 
reporting of treatment status in the past year as “unknown” by a survey participant, was 
interpreted as no treatment received for illicit drug use (NSDUH, 2017b).   
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Dataset Preparation 
Two inclusion criteria (age 18 - 25 years and with a diagnosis of OUD) guided the data 
extraction for this analysis.  Utilizing the Statistical Package for the Social Sciences (SPSS) 
Version 26, participants in the age group, 18 - 25 years old (CATAGE = 2) were filtered from 
the 2017 NSDUH dataset (SAMHDA, 2017).  This initial filtered group was all young adults.  
The young adults’ OUD status, contained in the dataset as the dichotomous variable, OPINMYR, 
was filtered from this initial group to extract those cases positive for OUD (OPINMR = 1).  With 
this young adult subset, data integrity checks were performed on all variables defined in the 
ABM and relevant to the study, to ensure that the data were appropriate for analysis and fit 
within the parameters defined for each variable.  All selected variables were coded numerically 
in the data analysis. 
As part of the dataset preparation, a collapsing of variables was performed to facilitate 
data analysis modeling.  Some covariates in this study contained a range of values that had large 
variability but small n.  The covariates were collapsed into interval values and recoded into a 
dummy variable.  The values for the variable EDUCATION, for example, were coded as one for 
fifth grade or less, two for sixth grade, three for seventh grade, four for eighth grade, followed by 
similar numerical sequencing for other grade levels.  The EDUCATION variable was analyzed 
as a categorical variable.  Homer and colleagues (2013) explained that the collapsing of levels 
maintains the structure of the covariate, maintains any relationships to the outcome, with a 
clearer picture of associations emerging. 
Each multiple level covariate (including multiple level dummy variables) with k levels 
was further manipulated by creating k - 1 dummy variables, to facilitate examination of 




associations between covariates and the outcome variable (treatment utilization).  One k level 
served as the baseline.  The other k -1 dummy variables took on one of two values.  Further, 
dichotomous variables were standardized to two discrete values (0 = No, 1 = Yes) to facilitate 
estimation of odds ratio generation in the logistic regression model. 
Covariates utilized in this study were not expected to contain missing data (NSDUH, 
2017b).  Missing values in variables not analyzed in this study were numerically coded in the 
2017 NSDUH dataset (NSDUH, 2017b).  The numerical values 85, 94, 97, 98 and 99 in the 
primary data source were used to represent bad data, don’t-know responses, refused, blanks and 
legitimate skips.  Legitimate skips referred to instances where a survey participant, skipped a 
question not relevant to him/her (veteran/military status).  In some cases, variables with missing 
values were statistically imputed and recoded (Table 7) with valid response categories by 
SAMHSA.  Imputation procedures were developed specifically for the NSDUH (NSDUH, 
2017). 
Beginning in 1999, the predictive mean neighborhood (PMN) method for imputation was 
implemented and was used for most variables in the national survey for drug use and health 
(NSDUH, 2017).  In 2015, the modified predictive mean neighborhood (modPMN) imputation 
method was implemented for a subset of drug variables (CBHSQ, 2019).  The predictive mean 
neighborhood method combined two commonly used imputation methods: non-model-based 
nearest neighbor hot deck (NNHD) and a modification of the model-assisted predictive mean 
matching (PMM) method, which matched a missing value to the observed value with the closest 
predicted mean.  The modification of the PMM allowed for application of the PMN method to 
both discrete and continuous variables, individually or jointly.  





Frequency counts were performed and screened for errors.  The age variable 
(CATAGE = 2) in the filtered dataset, for example, contained a value ≥ 18 and ≤ 25.  A crosstab 
with a second age variable (AGE2) which contained single age and age range values (18, 19, 20, 
21, 22-23, 24 - 25) validated the total number of young adults extracted via the CATAGE 
variable.  Verification of the dichotomous covariates gender, perceived need, other substance 
use, homelessness, arrest history, mental illness, OUD status, public assistance program and 
receipt of treatment was performed by screening for values (one representing a yes response and 
zero or two representing a no response).  The categorical covariates (marital status, 
veteran/military status, ethnicity, education, employment status, household size, sexual 
orientation, income, residence, insurance, self-reported health) had more than two value levels 
and were screened for their predetermined values.  The values for the questions that determined 
stigma (Did not get treatment because treatment might cause neighbors to have negative 
opinion? Did not get treatment because treatment might have negative effect on job? Did not get 
treatment because did not want others to know?) were also verified for their predetermined 
values.  These questions were selected based on previous research which utilized the NSDUH 
data to examine treatment utilization and stigma (Stringer & Baker, 2018). 
Total counts generated for each covariate were verified.  The total counts reflected the 
total number of cases filtered from the primary data source, the 2017 NSDUH dataset 
(SAMHDA, 2017).  The cumulative count of a specific variable was equivalent to the total 
number of cases meeting the inclusion and exclusion criteria for the data records extracted for 
the analysis.  Further, the data values for each covariate containing multiple levels (sexual 




orientation could be heterosexual or straight or lesbian or gay or bisexual) were equivalent to the 
nominal values specified in the survey codebook (referential integrity check).  All variables 
utilized in the analysis passed the referential integrity check.  
Data Analysis Plan  
The latest version of SPSS (v. 26.0) was used for the statistical analysis.  The data 
analysis was conducted in three phases.  In the first phase, descriptive statistics, including 
frequencies were calculated for all study variables.  This phase allowed for the exploration of 
covariates on the outcome variable without adjusting for any covariates.    
The second phase of data analysis was a bivariate analysis.  Specifically, a chi-square 
analysis to identify which covariates are associated with the outcome variable, treatment 
utilization (yes/no) at a statistically significant level (p < .05).  Covariates that were significantly 
associated with the outcome variable were included in the third phase of data analysis. 
The third phase of data analysis incorporated a hierarchical binary logistic regression 
model to examine the outcome variable as a function of all the covariates significantly associated 
with the outcome variable in the bivariate analysis (Phase 2).  The covariates were entered into 
the regression model in three blocks.  The first step included a block of significant Phase 2 
variables representing predisposing characteristics.  The second and third steps added other 
significant Phase 2 variables in blocks consistent with the structure of the ABM model.  The 
hierarchical binary regression model was examined for multicollinearity, goodness-of-fit (via the 
Pearson χ2 goodness-of-fit statistic), and overall statistical significance.  The relationships 
between the individual covariates and the outcome variable were assessed through the odds ratio 
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(including the 95% confidence interval), coefficient estimates, and the level of statistical 
significance for that covariate/response variable association.   
Assumptions Regarding the Data and Statistical Procedures 
General assumptions. The general assumptions were that the participants’ responses to 
survey questions were accurate and that there was a linear relationship between treatment 
utilization and the covariates.  Further, that the homogeneity of variance did not need to be 
satisfied.  The sample was also assumed to be sufficiently large for the goodness-of-fit, where 
the heuristic rule was that not more than 20% of the expected counts are less than five. 
Missing Data.   Imputation and recoding processes were applied to certain variables as 
part of the dataset preparation by SAMHSA.  The variables utilized in this study from the 2017 
NSDUH dataset did not contain missing data, except for data which was intentionally left blank 
in this public use dataset.   
Multicollinearity.  The main test assumption addressed within the binary logistic 
regression model was to assure that the level of multicollinearity between the covariates was 
acceptable.  Therefore, an analysis was conducted to assure that (variance inflation factor) VIF 
values were close to the value 1.0 and not greater than 2.0, a conservative value.   
Homoscedasticity, Linearity, Normal Distribution of Scores, Outliers. Binary logistic 
regression did not assume homoscedasticity, linearity, a normal distribution of scores, or, as a 
result, these assumptions were not tested.  In addition, the 2017 NSDUH variables used in this 
study were not continuous, but rather, categorical variables and contain data within a narrow 
range.  The undue influence of outlier data will therefore not be tested.   




Other Assumptions Associated with Regression.  Omission of variables in the primary 
dataset affected the interpretation of statistical results.  The variables selected to study the 
phenomenon in this study were accessible in the 2017 NSDUH and provided accurate feedback 
on the phenomenon being studied. 
Protection of Human Subjects 
The research protocol for this study met the criteria for exemption, in accordance with 
City University of New York (CUNY) HRPP Procedures: Human Subject Research Exempt 
from IRB Review.   
Summary 
The aim of this chapter was to describe the data analysis plan necessary to analyze the 
covariates in the conceptual model associated with treatment utilization among young adults with 
OUD in the U.S.  MOUDs have been described as the most successful treatment, but 
pharmacological data were unavailable in NSDUH to investigate the MOUD usage associated 
with predisposing, enabling, and needs characteristics.  Barriers to the use of MOUD were 
identified.  A more comprehensive understanding of additional characteristics which may explain 
OUD treatment utilization in this population was needed.  This study used a broad population-
based behavioral model to identify characteristics associated with treatment utilization for OUD.  
These characteristics were grouped into traditional and vulnerable domains and were modifiable 
or non-modifiable.  Identification of these characteristics, particularly those that were modifiable 
guided the development and enhancement of treatment strategies. 
Using descriptive and inferential statistics frequencies were generated.  Covariates with a 
statistical significance level (p < .05) through single predictor logistic regression analysis were 




identified.  Multivariable analysis was conducted to examine treatment utilization as a function 
of all the significantly related covariates at the bivariate level.  Results of the analyses were 
interpreted as they relate to the behavioral model that underpins this study.  Goodness-of-fit was 
assessed.  Associations between covariates and the outcome variable were assessed through the 
odds ratio, coefficient estimates, and the level of statistical significance for the 
covariate/outcome variable relationship.  
  




Chapter 4: Results 
The primary purpose of the proposed study was to determine the predisposing, enabling, 
and needs characteristics, as defined by ABM, that are associated with treatment utilization 
among young adults with OUD in the U.S.  The four hypotheses were that: 
1. among young adults with OUD in the U.S., certain predisposing characteristics 
(older age, female gender, never married, non-veteran/military status, perceive 
need of treatment, White race/ethnicity, having less than a high school education, 
not part of the labor force, parent communication, household size, non-
heterosexual, homelessness, arrest history, co-occurring substance use disorders, 
SUDs) are positively associated with treatment utilization. 
2. among young adults with OUD in the U.S., the enabling characteristics high 
income, having insurance coverage, residing in a large metropolitan area, and 
participating in one or more public assistance program are positively associated 
with treatment utilization.  
3. among young adults with OUD in the U.S., the needs characteristic self-reported 
health condition is positively associated with treatment utilization and  
4. among young adults with OUD in the U.S., the predisposing characteristic, mental 
illness, and the enabling characteristic, stigma, are negatively associated with 
treatment utilization.  
The outcome of the first phase in testing these hypotheses was a descriptive analysis of the 
study’s categorical variables of interest (Table 8).  




 Table 8 
Descriptive Analysis of Categorical Study Variables (n = 1,021) 
 
 
Variable        n           % 
 
 Outcome variable    
  Received treatment for illegal drug use in the past year   
  Received treatment at specialty facility only   12 1.2  
  Received treatment at non-specialty facility only  10 1.0  
  Received treatment at specialty and non-specialty facilities   55 5.4  
  Insufficient data to classify facility type    8 0.8  
  Did not receive illicit drug treatment  936 91.7  
 Received treatment – collapsed for inferential analysis  
  Yes  85 8.3  
  No  936  91.7  
 Covariates    
   Demographics    
   Age (years)    
     18   100  9.8  
     19   112  11.0  
     20   129  12.6  
     21   126 12.3  
     22 - 23   270 26.4  




   Male  504 49.4  
   Female  517 50.6  
 Marital status 
 
  
   Married  76 7.4  
   Divorced or separated  13  1.3  
   Never been married  932 91.3  
 Veteran/military status    
 
  In a reserve component  4 0.4 
   
   Now separated/retired from reserves/active duty  14 1.4  
   No military/veteran status   1003 98.2  
     




 Table 8 
Descriptive Analysis of Categorical Study Variables (n = 1,021) 
 
 
Variable        n           % 
 
 Health beliefs    
 
Perceived need 
   
 
During the past 12 months, did you need treatment or counseling for your use of prescription pain 
relievers?  
 
Yes  13 1.3 
 
 
No   26 2.6 
 
 





During the past 12 months, did you need treatment or counseling for your use of heroin?  
 
Yes  5 1.4 
 
 
No  8 1.1 
 
 
Refused/blank/legitimate skip  1,008 98.5 
 
 
   
  
   




Non-Hispanic White  608 59.5 
 
 
Non-Hispanic Black/African American  121 11.9 
 
 
Non-Hispanic Native American/Alaskan Native  14 1.4 
 
 
Non-Hispanic Native Hawaiian/Other Pacific Islander  6 0.6 
 
 
Non-Hispanic Asian  15 1.5 
 
 
Non-Hispanic More Than One Race  66 6.5 
 
 
Hispanic  191 18.7 
 




Less than high school diploma  176 17.2 
 
 
High school diploma/GED  351 34.4 
 
 
Some college credit, but no degree  345 33.8 
 
 
Associates degree  70 6.9 
 
 
College graduate or higher  79 7.7 
 




Employed full time  444 43.5  
 
Employed part time  215 21.1  
 
Unemployed  153 15.0  
 
Other (not in labor force)  209 20.5  
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Table 8 
Descriptive Analysis of Categorical Study Variables (n = 1,021) 
Variable      n          % 
Number of persons in household 
One person in household 55 5.4 
Two people in household 264 25.9 
Three people in household 241 23.6 
Four people in household 248 24.3 
Five people in household 124 12.1 
Six or more people in household 89   8.7  
Sexual orientation 
Heterosexual, that is, straight 816 79.9 
Lesbian or gay 42 4.1 
Bisexual 151 14.8 
Don’t know/refused 12 1.2 
Arrest history 
Yes 330 32.4 
No 688 67.4 
Don’t know/refused 3 0.3 
Mental illness 
No past year mental illness 539 52.8 
Past year mild mental illness 156 15.3 
Past year moderate mental illness 123 12.0 
Past year serious mental illness 203 19.9 
Other substance use 
Yes 966 94.6 
No 55 5.4 
Any health insurance 
Yes 876 85.8 
No 145 14.2 




 Table 8 
Descriptive Analysis of Categorical Study Variables (n = 1,021) 
 
 
Variable        n           % 
 




Less than $20,000  313  30.7 
 
 
$20,000 - $49,999  323  31.6 
 
 
$50,000 - $74,999  155 15.2 
 
 
$75,000 or more  230 22.5 
 
 
Resident location   
 
 
Large metropolitan  404 39.6 
 
 
Small metropolitan  407 39.9 
 
 
Non-metropolitan  210 20.6 
 
 Stigma 
   
 
 
Did not get treatment because treatment might cause neighbors to 




Yes  14 1.4 
 
 
 No  32 3.1 
 
 
 Refused/blank/legitimate skip  975 95.5 
 
 





Yes  12 1.2 
 
 
No  34 3.3 
 
 
  Refused/blank/legitimate skip  975 95.5 
 
 Did not get treatment because did not want others to know 
 
   
 
 
 Yes  7 0.7 
 
 
  No  39 3.8 
 
 








 Yes  281 27.5 
 
 
  No  740 72.5 
 
 Self-reported health condition 
  
  
  Excellent  147 14.4  
  Very good  390 38.2  
  Good  366 35.8  
  Fair/poor  118  11.6   
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The observations of selected ABM population characteristics derived from the descriptive 
analysis is presented below. 
Predisposing Characteristics.  
Approximately half the sample was between the ages of 22 and 25 years old 
(n = 270, 26.4%) and 24 - 25 years (n = 284, 27.8) of age, with approximately half of the sample 
reported as female (n = 517, 50.6%).  Most young adults’ marital status was, never been married 
(n = 932, 91.3%).  Additionally, almost the entire sample reported no military status (n = 1003, 
98.2%).  The perceived need variable showed approximately 95% refused, blank or legitimate 
skip rate.  The highest proportion of young adults with OUD were non-Hispanic White (59.5%).  
The remaining young adults were Hispanic 18.7%, Non-Hispanic Black/African American 
11.9%, and “other” 9.9%.  Approximately two-thirds of the young adults reported their highest 
level of education as high school diploma/GED (n = 351, 34.4%) or some college credit, with no 
degree totaling n = 345 (33.8%).  Most young adults were employed full time (n = 444, 43.5%), 
with the unemployed (n = 153, 15%) and those not part of the labor force (n = 209, 20.5%) 
accounting for one-third of the study sample.  A small percentage (n = 55, 5.4%) of the young 
adults reported only one person in their household.  Almost the entire sample had a heterosexual 
orientation (n = 816, 79.9%).  Approximately one-third (n = 330, 32.4%) of the young adults 
reported having an arrest history, with approximately half of the sample (n=539, 52.8%) having 
no mental illness within the past year.  A high percentage, almost 95% of the young adults, 
reported other substance use in the past year (n=966, 94.6%).     





Over three-quarters of the sample reported having health insurance (n = 876, 85.8%).  
More than a half reported having private health insurance (n = 567, 55.5%).  Approximately one-
third of the young adults reported their family income as less than $20,000 (n = 313, 30.7%) and 
nearly another third reported income of $20,000 - $49,999 (n = 323, 31.6%).  Residence was 
reported as large metropolitan (n = 404, 39.6%), small metropolitan (n = 407, 39.9%), or non-
metropolitan setting (n = 210, 20.6%).  Stigma evidenced a refused, blank, or legitimate skip rate 
of approximately 95% by the study participants.   Approximately one-quarter of young adults 
reported participating in one or more public assistance program (n = 281, 27.5%). 
Needs Characteristic.    
On a scale from excellent, very good, good, fair, to poor, most young adults described 
their health as very good (n = 390, 38.2%) or good (n = 366, 35.8%).  Only 14.4%, n = 147 
reported excellent health condition and 11.6%, n = 118 reported fair/poor health condition. 
  





The results of the bivariate analysis are displayed in Table 9.  The inclusion of covariates 




Chi-Square Analysis of Treatment Utilization (yes/no) with Covariates (n = 1,021) 
 




   
        
 Variable n % n % X²(df)   p  
             
Age (years)      6.82(5) .23  
18  93  (93.0) 7  (7.0)    
19  105 (93.8) 7  (6.3)    
20  121 (93.8) 8  (6.2)    
21  120 (95.2) 6  (4.8)    
22 - 23  244 (90.4) 26  (9.6)    
24 - 25  253 (89.1) 31  (10.9)    
        
Gender      .21 (1) .64  
 Male 460 (91.3)  44  (8.7)    
 Female 476 (92.1)  41  (7.9)    
        
Marital status      1.33(2) .51  
 Married 67  (88.2)  9  (11.8)    
 Divorced or separated 12  (92.3)  1  (7.7)  
 
 
 Never been married 857  (92.0)  75  (8.0)     
        
Veteran/military status      .39 (2) .82  
 In a reserve component 4 (100.0)
) 
0  (0.0)    
 Now separated/retired from 
reserves/active duty 
13  (92.9)  1  (7.1)     
 No veteran/military status 919  (91.6)  84  (8.4)    
        
Race/ethnicity     9.72 (3) .02  
 White 547 (90.0) 61 (10.0)    
 Black/African American 118 (97.5) 3 (2.5)    
 Hispanic 180 (94.2) 11 (5.8)    
Other (Native American/Alaskan 
Native, Native Hawaiian/Other Pacific 
Islander, Asian, and more than one 
race) 
91 (90.1) 10 (9.9)    
        






Chi-Square Analysis of Treatment Utilization (yes/no) with Covariates (n = 1,021) 
 




   
        
 Variable n % n % X²(df)   p  
             
Highest level of education     1.48 (4) .69  
 Less than high school diploma 158 (89.8)  18 (10.2)    
 High school diploma/GED 316 (90.0)  35 (10.0)  
 
  
 Some college credit, but no degree 319 (92.5)  26 (7.5)    
 Associates degree 66 (94.3)  4 (5.7)    
 College graduate or higher 77 (97.5)  2 (2.5)     
        
Employment status     19.62 (3) .001  
 Employed full time 417 (93.9)  27 (6.1)    
 Employed part time 202 (94.0) 13 (6.0)    
 Unemployed 127 (83.0)  26 (17.0)    
 Other (not in labor force) 190 (90.9)  19 (9.1)     
        
Number of persons in household     12.20(5) .03  
 One person in household 52 (94.5) 3 (5.5)    
 Two people in household 247 (93.6) 17 (6.4)     
 Three people in household 213 (88.4) 28 (11.6)    
 Four people in household 230 (92.7) 18 (7.3)    
 Five people in household 118 (95.2)  6 (4.8)    
 6 or more people in household 76 (85.4) 13 (14.6)    
        
Arrest history     69.94 (1) .001  
Yes 269 (81.5) 61 (18.5)    
 No (includes don’t know/refused) 667 (96.5) 24 (3.5)     
        
Mental illness     5.03 (3) .17  
 No past year mental illness 504  (93.5) 35 (6.5)    
 Past year mild mental illness 140  (89.7) 16  (10.3)    
 Past year moderate mental illness  110  (89.4) 13 (10.6)    
 Past year serious mental illness 182  (89.7) 21 (10.3)    
        
Other substance use     5.28(1) .02  
 Yes 881 (91.2) 85 (8.8)    
 No 55 (100.0) 0 (0.0)    
        
TREATMENT UTILIZATION FOR OPIOID USE DISORDER 
63 
Table 9 





Variable n % n % X²(df)   p 
Sexual orientation .73 (3) .87 
 Heterosexual, that is, straight 747 (91.5) 69 (8.5) 
 Lesbian or gay 40 (95.2) 2 (4.8) 
 Bisexual 138 (91.4) 13 (8.6) 
 Don’t know/refused 11 (91.7) 1 (8.3) 
Residence 1.26 (2) .53 
 Large metro 370 (91.6) 34 (8.4) 
 Small metro 377 (92.6) 30 (7.4) 
 Nonmetro 189 (90.0) 21 (10.0) 
Any health insurance .45(1) .50 
 Yes 801 (91.4) 75 (8.6) 
 No 135 (93.1) 10 (6.9) 
Private insurance .25(1) .62 
Yes 522 (92.1) 45 (7.9) 
 No 414 (91.2) 40 (8.8) 
Family income 1.48(3) .69 
 Less than $20,000 289 (92.3)  24  (7.7) 
 $20,000 - $49,999 293 (90.7)  30 (9.3) 
 $50,000 - $74,999 145 (93.5)  10 (6.5) 
 $75,000 or More 209 (90.9)  21 (9.1) 
Participated in one or more public assistance program(s) 8.67(1) .003 
 Yes 246 (87.5) 35 (12.5) 
 No 690 (93.2) 50 (6.8) 
Self-reported health condition 2.77 (3) .43 
 Excellent 139 (94.6) 8 (5.4) 
 Very good 359 (92.1) 31 (7.9) 
 Good 330 (90.2) 36 (9.8) 
 Fair/poor 108 (91.5) 10 (8.5) 
Few covariates (race/ethnicity, employment status, household size, arrest history, other 
substance use, participated in one or more public assistance programs) were significantly 




associated, p < .05, with treatment utilization.  The covariate race/ethnicity reflected that 
Black/African Americans (n = 3, 2.5%) had the lowest rate of treatment utilization relative to 
White persons, Hispanic persons, and other races.  White young adults (n = 61, 10.0%) had the 
highest treatment utilization rate among all races/ethnicities, even though it was still quite low.  
In the race/ethnicity category, other races, (n = 10, 9.9%) tended to utilize treatment more than 
Hispanic and Black/African American young adults.  
Regarding employment status, the unemployed young adults (n = 26, 17.0%) evidenced a 
higher rate of treatment utilization relative to the employed (full time or part time) or those not in 
the labor force.  Young adults who reported having an arrest history (n = 61, 18.5%) showed a 
higher rate of treatment utilization relative to those with no arrest history.  The lowest rate of 
treatment utilization was reported among a household size of one (n = 3, 5.5%) and a household 
size of 5 (n = 6, 4.8%) relative to other household sizes of two, three four, or six plus persons.  
Those who reported other substance use (n = 85, 8.8%), reported a higher rate of treatment 
utilization relative to those who had not (n = 0, 0.0%).  This variable, other substance use could 
not be included in the multivariate model as there were zero young adults with no other 
substance use and treatment utilization.  Lastly, young adults’ participation in one or more public 
assistance programs (n = 35, 12.5%) showed a higher treatment rate relative to those who did not 
participate in one or more public assistance programs. 
Multivariable Analysis 
The results of the multivariable analysis are displayed in Table 10.  The hierarchical 
binary regression model examined the association of significant covariates (race/ethnicity, 
employment status, household size, arrest history, participation in public assistance programs) 




with the outcome variable, treatment utilization.  The model showed no evidence of 
multicollinearity, as all VIF values were approximately 2.5 or lower.  A VIF of 2.0 was 
considered extremely conservative with 2.5 still classified as conservative (Field, 2009).  The 
overall regression model was statistically significant p < .001 and classified 92.0% of cases 
correctly.  Results from the final step (Step Three) of the regression model answered the research 
question and supported or rejected the study’s hypotheses.   
 
Table 10 
A Hierarchical Binary Logistic Analysis Examining Treatment utilization (n = 1,021) 
 
 Variable   B (SE)   Wald X²        OR (95% CI)       p  
 Step 3 
 Race/ Ethnicity 
  White (Reference Group) 
      Black  ₋2.15 (.63)  11.56  .12 (.03-.40)  .001 
  Hispanic    ₋.74 (.37)   4.08  .48 (.23-.98)  .04 
  Other    ₋.06 (.39)     .04  .95 (.43-2.00)  .85 
  
  Unemployed (Reference Group) 
      Employed Full-time  ₋1.19 (.33)  12.98  .30 (.16-.58)  .001 
  Employed Part-time  ₋1.05 (.39)    7.20  .35 (.16-.75)  .007 
  Other (not part of labor force)    ₋.56 (.36)    2.46  .57 (.29-1.15)  .12 
 Household Size 
  Six or more people (Reference Group) 
      One person    ₋.65 (.71)     .84  .52 (.13-2.11)  .36 
  Two people    ₋.68 (.44)         2.38  .51 (.22-1.20)  .12 
  Three people     .03 (.41)      .01 1.03 (.46-2.30)  .94 
  Four people    ₋.44 (.43)    1.03   .65 (.28-1.50)  .31  
  Five people  ₋1.24 (.56)    4.93   .29 (.10-.87)  .03 
 History Arrest   1.82 (.26)  48.44     6.17 (3.70-10.31)    .001 
 Participated in Public Assistance Program(s)     .45 (.27)    2.89     1.58 (.93-2.66)      .09 
 
 
Step 1: Model = X²(11) = 44.23, p < .001. 
Step 2: Model = X²(12) = 103.05, p <  .001. 
Step 3: Model = X²(13) = 105.88, p < .001. 
 





Hypothesis One.  Hypothesis one stated that among young adults with OUD in the U.S., 
the predisposing characteristics (older age, female gender, never married, non-veteran/military 
status, perceive need of treatment, White race/ethnicity, having less than a high school 
education, not being part of the labor force, parent communication about the danger of tobacco, 
alcohol or drugs, household size, non-heterosexual, homelessness, arrest history, other 
substance use) are positively associated with treatment utilization.   
The four covariates in hypothesis one, determined to be significantly associated with 
treatment utilization (race/ethnicity, employment, household size, arrest history) in the 
intermediary step were entered into the model in blocks reflecting the ABM’s structure of 
predisposing, enabling and needs characteristics.  Homelessness was not analyzed in the 
intermediary step as the public use file contained no data for the covariate, homelessness.  The 
significant covariate, other substance use, significant in the intermediary step, was not entered 
into the model as there were zero subjects in one of the categories (young adults who did not use 
other substances and did not utilize treatment).  
 Findings showed that young Black adults were eight times less likely, and Hispanics were 
two times less likely to utilize treatment compared to young non-Hispanic White adults.  Young 
adults who reported being employed were less likely to utilize treatment compared to young 
adults who were unemployed.  A young adult employed full-time was more than three times less 
likely to utilize treatment while a part-time employee was nearly three times less likely to utilize 
treatment compared to the unemployed young adult.  Young adults not in the labor force did not 
maintain a significant association with treatment utilization.  Young adults residing in a five-
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person household were over three times less likely to utilize treatment compared to a young adult 
residing in a six-person plus household.  Young adults reporting an arrest history were more than 
six times more likely to utilize treatment compared to those who did not have an arrest history.  
Arrest history was positively associated with treatment utilization in step three of the model.  
Hypothesis one was therefore partially supported.   
Hypothesis Two.  Hypothesis two stated that among young adults with OUD in the U.S., 
the enabling characteristics high income, having insurance coverage, residing in a large 
metropolitan area, and being on one or more public assistance program(s) are positively 
associated with treatment utilization.  Being on one or more public assistance program(s) was 
the only covariate in this hypothesis that remained significant in the intermediary step.  In the 
model however, this covariate did not remain significant.  Hypothesis two was not supported. 
Hypothesis Three.  Hypothesis three stated that among young adults with OUD in the 
U.S., the needs characteristic self-reported health condition is positively associated with
treatment utilization.  In the intermediary step, this covariate was not significantly associated 
with treatment utilization and therefore not entered in the model.  Hypothesis three was not 
supported. 
Hypothesis Four.  Hypothesis four stated that among young adults with OUD in the 
U.S., the predisposing characteristic mental illness and the enabling characteristic stigma are
negatively associated with treatment utilization.  In the intermediary step, mental illness was not 
significantly associated with treatment utilization.  Stigma was excluded from the intermediary 
step.  Hypothesis four was not supported. 




The Research Question 
The research question formulated for this study was: What are the predisposing, enabling, 
and needs characteristics as posited in the Andersen Behavioral Model that are significantly 
associated with treatment utilization among young adults with opioid use disorder in the United 
States?  Step three of model showed that the ABM’s predisposing characteristics significantly 
associated with treatment utilization were race/ethnicity, employment status, household size and 
arrest history.  These associations, except for arrest history were weak.  The various levels within 
the covariates with a significant association (race/ethnicity, employment status and household 
size) were not all significant. 
Interaction Effect 
An interaction effect to examine age as a moderator of residence and treatment utilization 
was added to the final model.  Age did not moderate the association between residence location 
and treatment utilization at a statistically significant level, B = .03, SE = .11, Wald X² = .06, 
OR = 1.03, 95% CI [.83, 1.27], p = 81) within the limited power of testing. 
Summary 
This study focused on the ABM’s population characteristics (predisposing, enabling, 
needs) to determine associations between selected characteristics and treatment utilization among 
young adults with OUD in the U.S.  Treatment utilization was examined in a regression model as 
a function of all covariates with significant associations in the intermediate step.  The results in 
step three of the model were used to evaluate the statements made in the study’s hypotheses.  
Two statistical analyses (bivariate analysis, multivariable analysis) were conducted to reveal a 




more limited set of covariates (race/ethnicity, employment status, household size and arrest 
history) predicting treatment utilization. 
  




Chapter 5: Discussion 
Most previous OUD treatment utilization studies focus on the adolescent or adult 
population.  Additionally, earlier studies did not examine the association of the multi-
dimensional population characteristics in the ABM with treatment utilization, specifically among 
the young adult population with OUD in the U.S.  Extrapolating treatment utilization results 
from previous studies to the young adult population with OUD is therefore difficult, making it 
necessary to conduct this study.  Other principal reasons for this study are the upward trend of 
mortality rates, involving opioids misuse (NIDA, 2020).  Additionally, young adults have a 
higher prevalence of OUD and a greater OUD treatment need when compared to older adults.  
Understanding treatment utilization among young adults with OUD in the U.S. is important too, 
for planning strategies to address any deficiencies in treatment utilization among this population.  
This study addresses treatment utilization in the understudied young adult population with OUD 
in the U.S.  It tests the association of treatment utilization with a broad array of demographics, 
and social characteristics, personal/family resources and community resources posited in the 
ABM. 
The ABM characteristics consist of predisposing characteristics (age, gender, marital 
status, veteran status, health belief, ethnicity, education, employment, family size, immigration 
status, literacy, living conditions, sexual orientation), enabling characteristics (insurance, 
income, residence, religion, self-help skills, social service resources, being on public assistance 
program[s], transportation), and need characteristics (self-reported health condition, evaluated 
health condition).  Considering the propositions of the ABM, selected ABM characteristics are 
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analyzed to determine their association with treatment utilization among young adults with OUD 
in the U.S. 
Treatment Utilization 
Findings show that treatment utilization is low among young adults with OUD in the U.S. 
within the past year.  More than 90% of this study’s sample do not utilize treatment, although all 
have a diagnosis of OUD in the past year.  This finding could not be compared to the results of 
similar studies as reports on treatment utilization specifically among young adults were not 
found.  Studies analyzing national data on treatment utilization in the past year among the U.S. 
population, inclusive of young adults, report low rates of OUD treatment utilization (Becker, 
et al., 2008; Romo, et al., 2018; Saloner & Karthikeyan, 2015; Wu, et al., 2016).  Between 2000 
and 2004, for example, less than 16% of the U.S. population with OUD, are reported as receiving 
any treatment (Becker, et al., 2008).  Most individuals 12 years and older who needed OUD 
treatment, from 2010 to 2014 are reported as utilizing no treatment (Romo, et al., 2018).  The 
same observation is made in the period 2009 and 2013, with 21.5% of the U.S. population 
reporting treatment use for OUD (Saloner & Karthikeyan, 2015).   
These unchanging treatment patterns among the U.S. population may be explained by 
systemic level or individual level factors.  At the systemic level there are limitations placed on 
the number of physicians, nurses, and other healthcare providers who can prescribe BUP 
(Alderks, 2017; SAMHSA, 2019c; The President’s Commission, 2017; Thomas, et al., 2014).  
The existence of office-based OUD treatment barriers (insurance pre-approval / reimbursement, 
stigma, perceptions of “difficult” patients, and legal restrictions specific to sublingual BUP 
prescribing) are systemic reasons (Andraka-Christou & Capone, 2018; Haffajee, et al., 2020).  




Healthcare providers unfamiliarity with the formulations of MOUDs are included (Haffajee, 
2020).   
At the individual level, young adults are unwilling or ready to stop using illicit opioids 
(Liebling, et al., 2016).  They fear negative opinions when others find out about their substance 
use or have perceptions of being able to handle the problem on their own.  Additionally, the adult 
population (which includes young adults) with SUDs and comorbid conditions (mental illness) 
tend to obtain mental health services rather than substance abuse treatment (Ali, et al., 2015; 
Romo, et al., 2018).  Further, whether a need is perceived for treatment or not, adults do not seek 
treatment (Ali, et al., 2015; 2017).  Homelessness affects OUD treatment utilization too 
(Liebling, 2016).   Liebling and colleagues (2016) reported a decreased likelihood of treatment 
utilization with homelessness (Liebling, et al., 2016).   
Associations of ABM Characteristics with Treatment Utilization 
The analysis is performed on data extracted from a large, nationally representative 
sample of individuals with SUDs in the U.S.  The data do not allow for the analysis of all the 
prospective factors associated with treatment utilization among young adults with OUD.  
However, significant associations are found between the selected ABM characteristics and 
treatment utilization for OUD.  These associations provide valuable knowledge for policies 
aimed at addressing treatment utilization for OUD among young adults in the U.S.  The ABM 
predisposing characteristic, arrest history is six times more likely to be associated with treatment 
utilization.  Race/ethnicity, employment status, and household size are less likely to be 
associated with treatment utilization.   





Findings reveal that there are more non-Hispanic White young adults with OUD than 
Black and Hispanic young adults.  Prior studies confirm this finding (Liebling, et al., 2016; 
Romo., et al., 2018; Saloner & Karthikeyan, 2015).  Several reasons are suggested for the 
differences based on race/ethnicity (Hoffman, et al., 2016; Netherland, & Hansen, 2016; 
Pouget, et al., 2018).  First, racial bias exists in the prescribing of pain medications for racial 
minorities and in the perceptions of others’ pain (Hoffman, et al., 2016; Pouget, et al., 2018).  
Healthcare providers rate Black persons’ (vs. white persons’) pain lower.  This false belief, that 
Black persons feel less pain than White persons contributes to racial disparities in pain 
assessment and treatment, and consequently higher exposure to prescription opioids among 
Whiter persons.  Second, it has been reported that minorities have less access to prescription 
opioids compared to White persons (Friedman, et al., 2019; Singhal, et al., 2016).  This lack of 
access to prescription opioids may also arise from the mistrust of the healthcare system based on 
community-reported or individual experiences of racism (Smith, 2010).  Such mistrust is not 
surprising, considering revelations of unethical research practices (Tuskegee Syphilis Study, the 
misappropriation of Henrietta Lacks's cells for research; CDC, 2021; Lucey, et al., 2009).   
As in previous studies (Liebling, et al., 2016; Romo, et al., 2018; Wu, et al., 2016), this 
study found that the Black/African American young adult utilized treatment less than Whites.  
This may speak to the fact that Blacks are more likely to live in socially disadvantaged 
communities, where there may be fewer facilities to provide access to all MATs for OUD 
(Goedel, et al., 2020; Reboussin et al., 2015; Sampson, 2011; Wallace & Muroff, 2002).  
Additionally, minorities may be less willing to pursue treatment due to the potential for child 




welfare involvement (CWIG, 2021).  The Child Abuse Prevention and Treatment Act of 2016 
and Family First Prevention Services Act of 2018 require states to have laws, policies, and/or 
procedures requiring health-care providers involved in the delivery or care of infants to notify 
child protective services if a child is identified as being affected by substance abuse, withdrawal 
symptoms resulting from prenatal drug exposure or our occurrences of fetal alcohol spectrum 
disorders. 
Employment  
Consistent with other studies relating to prescription drug misuse in the U.S. population 
(Choi, et al., 2019; LeClair, et al., 2015; Romo, et al., 2018), this study finds that most young 
adults with OUD in the U.S. are employed at least part time.  Additionally, this study finds that 
employed young adults utilize treatment less than unemployed young adults and those not in the 
work force (includes students, persons keeping house or caring for children full time, retired or 
disabled persons, or other persons).  This finding is confirmed among a statewide sample of 
young adults, among the over 12 years old population and among an adult population (Liebling, 
et al., 2016; NSDUH, 2017b; Romo, et al. 2018).  The employed are often covered by employer-
mandated insurance plans (IRS, 2020).  Many employer plans establish coverage for SUD 
treatment as mandated by the ACA.  However, a full array of substance abuse treatment benefits 
(residential treatment, all FDA approved MOUDs) are not covered (NCASA, 2017). 
Additionally, with difficulties in accessing timely treatment due to delays in obtaining 
insurance authorizations, and excessively high out-of-pocket costs (copayments), the motivation 
to seek treatment is minimalized, leading individuals with SUD to forego treatment.  For 
individuals with limited income (unemployed, those not in the labor force), Medicaid and other 
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affordable state plans provide a range of substance abuse treatment options (inpatient and 
outpatient treatment, pharmacologic treatment for opioids; CMS, 2016; Healthcare.gov, n.d.). 
Household Size 
Household size is defined as a count of the number of family members greater than or 
equal to 12 years old in the household (NSDUH, 2017).  Most young adults (94.5%) do not live 
alone.  Young adult living in a household with five persons is over three times less likely to 
utilize treatment compared to a six-person plus household.  Probing further to obtain a clearer 
understanding of the association of household size with treatment utilization is not 
accomplishable as this is an epidemiological study, that is retrospective.  In contrast, a qualitative 
or mixed method study could have provided that information.  The household size association 
with treatment utilization in step three of the regression analysis is partially explained by 
evidence in other studies which indicate that the treatment preference of individuals with OUD is 
to have family involvement in their substance use treatment (Andraka-Christou, et al., 2021; 
Ariss, et al., 2020; Hogue, et al., 2018).  
Arrest History 
 Young adults with an arrest history are more likely to utilize treatment for OUD.  Other 
studies support this finding (Nam, et al., 2016; Romo, et al., 2018; Choi, et al.  2019).  
Individuals with SUDs are often ordered to treatment programs (alternative-to-prison, 
community-based supervision, community-based treatment, prison-based) following an arrest 
(Andraka-Christou, et al., 2020; Belenko, et al., 2013; NADCP, 2015).  This may be to satisfy 
release considerations.  Becoming involved in a treatment program too, may also reflect a 
person’s own decision to show the courts that they are making positive changes.    




Other ABM Characteristics 
The analysis of national data prior to 2017, show that more males than females in the 
adolescent and young adult population misuse opioids (Hudgins, et al., 2019).  Wu and 
colleagues (2016), analyzing 2005-2013 national data, make the same observation among the 
≥ 12-year-old population.  This contrasts with findings in this study which showed that the 
female and male genders have equal prevalence of OUD.  This equalizing of prevalence of OUD 
rates among men and women, indicates an obvious rise in OUD among young adult women.  
This occurrence is explained by reports in other studies (Compton, et al., 2016; Koons, et al., 
2018).  Compton and colleagues’ (2016) review article reports shifts in demographic 
characteristics associated with heroin use, an illicit opioid.  Firstly, they report increase rate of 
heroin usage among young adults, in both genders, but more among women than among men 
(Compton, et al., 2016).  This evidence is based on the analysis of data from NSDUH and 
National Vital Statistics from 2002-2013.  Koons and colleagues (2018) literature commentary 
indicate that women more than men are more likely to be prescribed opioids (based on the 
analysis of data from the 1999-2012 National Health and Nutrition Examination Survey).  
Women are therefore placed at higher risk for opioid misuse and therefore subsequent disorder.     
Further, women are reported to have higher prevalence of gender-based sexual and 
domestic violence with ensuing psychological effects which increase vulnerability to opioid 
misuse (D’Inverno, et al., 2019; Koons, et al., 2018).  D’Inverno and colleagues (2019) analyzed 
data on intimate partner violence, sexual violence and stalking victimization of adult women and 
men (≥ 18 years) from the U.S. National Intimate Partner and Sexual Violence Survey. 
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As it pertains to the ABM characteristic, educational status, most young adults who do 
not utilize treatment, only attain a high school diploma/GED or some college credit, but no 
degree.  This finding is consistent with studies conducted prior to 2017 or studies which analyzed 
data prior to 2017, examining the young adult and the adult populations’ prescription drug 
misuse and/or SUD treatment utilization (Liebling, et al., 2016; McCabe et al., 2018; Romo, 
et al., 2018).  It may be too, that some young adults have no interest in pursuing higher education 
at this developmental stage of their lives.  LeClair and colleagues (2015) report that young 
adulthood is marked by experimentation.  Experimentation at the young adult stage motivates 
risk behaviors (substance use) that change the educational trajectories of young adults.  
Young adults reporting treatment utilization has either mild, moderate, or serious mental 
illness.  Previous analysis of adults ≥ 18 years in a national dataset shows similar findings 
(Romo, et al., 2018).  It is not surprising that mental illness occurs with OUD.  OUD is a 
subgroup of SUD, and SUD have been reported to occur in conjunction with mental 
comorbidities (Ali, et al.,2015; Butler, et al., 2017; Defoe, et al., 2019; Haughwout, et al., 2016; 
Jones, et al., 2017; Rodriguez-Sejias, et al., 2017; Romo, et al., 2018; Wu, et al., 2016; 
Tragesser, et al., 2013).  Additionally, individuals with co-occurring SUDs and mental illness 
may have different patterns of treatment (Novak, et al., 2019).  Some may receive substance use 
treatment.  Others may obtain mental health services rather than substance use treatment 
(Ali, et al., 2015).  Yet still, some may not be well served within the existing health care system 
where SUD and mental illness treatment are not integrated or coordinated appropriately. 
A noteworthy finding is that young adults residing in small and large metropolitan areas 
are less likely to utilize treatment for OUD compared to those in rural/non-metropolitan areas.  




This is unexpected as The President Commission’s 2017 report states that treatment utilization is 
less prevalent in rural (vs metropolitan) areas due to barriers like the unavailability of MOUDs 
and DEA-waivered physicians to treat OUD.  This reversal may be due to NIDA and other 
federal agencies funding of several initiatives to offer SUD services in rural areas, with state and 
local communities developing best practice responses which are implemented by public health 
systems (HRSA, 2021, NIDA, 2017a).  The National Center for Health Statistics, August 2019 
Data Brief No. 345 confirms this reversal (Hedegaard, et al., 2019).  It may be too, that these 
young adults, diagnosed as having an OUD, may not know that they have a substance problem.  
Thus, treatment utilization is not sought. 
Delimitations 
This study is delimited by the variables present in the 2017 NSDUH dataset selected for 
this study (SAMHDA, 2017).  Further, the individuals in the surveyed population were defined 
as U.S. civilians who were noninstitutionalized and residing within the U.S. (Bose, et al., 2017).  
Participants were residents of households (including civilians living in housing on military 
bases), or individuals in non-institutional group quarters or homeless individuals with no 
permanent address but housed in shelters or single rooms in hotels (Bose, et al., 2017).  A total of 
56,276 individual survey responses were collected of which 13,840 were determined to be young 
adults possibly eligible for the study.  Members of the active-duty military, individuals in 
institutional group quarters (long-term care hospitals, institutional group quarters like 
prisons/jails, correctional facilities, nursing homes, mental institutions), and homeless 
individuals with no permanent address and not housed in a shelter were excluded.  
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Limitations 
Because of the retrospective nature of a secondary analysis, study participants could not 
be probed for additional information to provide a clearer understanding of associations.  Lack of 
variables of interest, blanks/refused responses, or legitimate skips rates > 87% in the NSDUH 
dataset makes it impossible to obtain findings on (a) differences in treatment utilization among 
young adults (who sought treatment vs those who did not seek treatment) as it relates to specific 
MOUD, (b) the interaction effect of MOUDs and age (c) the interaction effect of treatment 
physical location and residence location, (d) treatment utilization association with treatment 
access, or (e) treatment utilization association and medical comorbidities. 
SAMHSA utilizes one-time interviews, self-reports, and computer-assisted 
questionnaires to collect data for the 2017 NSDUH dataset (NSDUH, 2017b).  These data 
collection methods unintentionally introduce bias resulting from under-reporting, over-reporting, 
or invalid/inconsistent responses (SAMHSA, 2018a).  The value of the data is, therefore, 
dependent on the honesty, memory recall, and accuracy of the survey participant.  Further, with 
one-time interviews, the data collected, provides an overview of possible characteristics that may 
be associated with treatment utilization at a specific point in time rather treatment utilization 
changes over time.  
Actions were taken by SAMHSA to mitigate biases (SAMHSA, 2018a).  The use of an 
audio computer-assisted data collection tool provided participants with a vastly private and 
confidential setting in which to respond to questions.  The goal was to increase the level of 
honest reporting of drug use behaviors.  Further, answers provided to sensitive questions were 
gathered through a computerized data collection tool, without interviewers having knowledge of 




answers.  With respect to one-time interviews, SAMHSA had produced datasets on drug use and 
health on a yearly basis, though not necessarily interviewing the identical individuals each year.  
Inconsistent responses from survey participants were addressed by deterministic editing or by 
use of imputation methods.  Deterministic editing to correct inconsistent responses is appropriate 
when a unique association exists between independent variables and covariates (determining 
gender from relationships [son, daughter] to head-of-household).  Unambiguous determinations 
are not always possible (gender from the cousin relationship), in such cases, the inconsistent 
response was replaced with statistically imputed data. 
Implications 
Practice and Policy 
This study identifies various ABM characteristics (race/ethnicity, employment status, 
household size and arrest history) that are associated with treatment utilization among young 
adults in the U.S.  Employment status and household size may not be directly modifiable to 
affect treatment utilization.  A young adult with OUD, who is employed (part time or full time) 
should not face insurance barriers to treatment utilization.  Insurance options that provide 
unlimited substance use treatment visits and affordable copayments for substance use treatment 
should become part of employers’ and government’s insurance offerings.  Tax incentives can be 
utilized to persuade employers to comply. 
The household size of a young adult may not be directly modifiable.  However, with the 
implication that individuals with OUD prefer to have family involvement in their substance 
treatment (Andraka-Christou, et al., 2021; Ariss, et al., 2020; Hogue, et al., 2018), it may be 
necessary to place young adults with no family support, into special environmental settings 
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where they are motivated to utilize treatment by healthcare providers, counselors, and their peers 
in similar situations. 
NIH endorses various practical treatment-related strategies address opioid overdose 
(NIH, 2018).  Table 11 lists these strategies.   
Table 11 
NIH Treatment-Related Strategies for Treating Opioid Use Disorder 
• 911 Good Samaritan Laws to prevent bystanders from putting themselves at risk of
arrest when seeking emergency care for an opioid overdose
• academic detailing to help healthcare providers use best practices
• eliminating prior-authorization requirements for MOUDs
• initiating BUP-based therapies in emergency departments for untreated OUD
• screening for fentanyl in routine clinical toxicology testing
• targeted NAL distribution
• use of MOUDs
Results of this study should inform the assessment of these NIH strategies to determine 
their effectiveness in contributing to treatment utilization among young adults.  The use of 
MOUDs should be made equally accessible to Black, Hispanic, non-Hispanic Asian persons 
including other persons, who are less likely to utilize OUD treatment compared to White 
persons.  In addition, identifying minority areas underserved by existing OUD treatment 
facilities, on a state-by-state basis, may be necessary.  The identification of underserved minority 
areas may inform policy makers on high need areas requiring resources for MOUDs. 
This study’s findings show that young adults are more likely to utilize treatment, if they 
have an arrest history.  Having an arrest history should not be the gateway to OUD treatment for 




young adults. It may however be prospectively modifiable to prevent young adults from being 
arrested or re-arrested for misuse of opioids or opioid-related infractions.  Strategies that 
implement interventions, policies, and practices (a) prescription drug monitoring programs 
(Bohnert, et al., 2018), (b) prescribing of non-pharmacologic treatments for pain (Heyward, 
et al. 2018; Lin, et al., 2018; Volkow, & Collins, 2017), (c) counterdrug laws to diminish illicit 
foreign and local drug supply and drug trafficking, (d) national prescription drug take-back, 
(e) increase control of synthetic drugs from China (DOJ/DEA, 2017), and (f) drug enforcement 
laws (DOJ/DEA, n.d.) may already have a positive impact in diminishing the number of young 
adults with an OUD and possibly facing arrest.  Implementation of childhood and adolescent 
prevention approaches, for example, peer environment modification, and adverse childhood 
experiences considerations (ACE; Dube, et al., 2003; Enoch, 2011; Hawkins, et al., 1992; 
Volkow & Boyle, 2018) that address early risk factors is warranted. 
   On the contrary, funding should be made available for studies to expand knowledge on 
the characteristics of those young adults who are not arrested, and to identify those who may be 
at-risk for opioid use.  Prevention interventions could then be implemented using the outcome of 
these studies.  NIH is already supporting initiatives to develop evidence-based interventions to 
prevent opioid use disorder (NIH, 2019).  Unraveling the details of an arrest (first time 
arrest/repeat offender, opioid-related, charges, fines, sentencing, peer environment, ACE, 
treatment status, MOUDs utilized) is essential in making strategic recommendations for practical 
usage of this study’s findings on arrest history.  Unfortunately, the specifics on arrest history 
could not be examined in this study due to data limitations in the 2017 NSDUH.   




The analysis of employment data related to young adults with OUD show that the 
employed young adult is less likely to use treatment when compared to the unemployed young 
adult and those young adults not in the labor force.  Employment is a modifiable characteristic.  
However, employment modifications may not be simple for young adults, particularly if they do 
not have higher education.  The high prevalence of OUD among the employed should serve as an 
indicator that employers, as stakeholders in their organizations, need to be educated on the 
concerns of OUD and OUD treatment utilization.  Employers can look beyond substance abuse 
legislation and contribute to the treatment needs of their employees, by possibly influencing the 
level of healthcare benefits included in employer sponsored insurance plans (removal of 
substance use treatment limits, eliminating prior authorizations, lessening copayments), that limit 
OUD treatment utilization.  The Affordable Care Act requires most insurers to cover treatment 
for SUD (NIOSH, 2019).  Many insurers, however, may not cover all types of treatment for SUD 
or provide the appropriate pharmacy benefits, as the ACA do not stipulate details in the SUD 
treatment mandate (Abraham, et al., 2017).  NIH, 2018 however, recommends eliminating prior-
authorization requirements for MOUDs. 
This study’s findings suggests that young adults with OUD and co-occurring mental illness 
(over 89%) are not utilizing treatment for OUD.  There is a need to integrate and coordinate 
behavioral health care, as most young adults with OUD in the U.S. are shown to have a mild, 
moderate, or serious mental illness.  A 2015 forum of clinical and public health experts convened 
at the Center for Mental Health and Addiction Policy Research at Johns Hopkins University and 
recommended effective policy communication strategies to increase public support for policies 
benefiting people with mental illness and SUD (McGinty, et al., 2018).  Findings from this 




forum which may be beneficial for young adults with OUD and co-occurring conditions (mental 
illness) include the use of sympathetic narratives (stories that humanize the experiences and 
struggles of individuals with mental illness or SUD).  The aim of this strategy is to allow 
audiences to understand societal problems relating to mental illness and SUD and to increase 
support for public policies that benefit people with mental illness and/or substance use disorders.  
Additionally, the use of messaging which highlights structural barriers to treatment (inadequate 
insurance coverage, limited access to provider, unavailability of evidence-based services) may 
increase the public’s support for allocation of additional resources for mental illness and SUD 
treatment.   Funding opportunities continue to be awarded to address OUD in rural/non-
metropolitan areas (NIDA, 2017a).  It is important to ensure that there is equity in OUD funding. 
These practical strategies may positively influence treatment utilization and may be 
valuable components to any drug treatment policy.  The effectiveness of drug treatment policies 
had been examined and findings indicated that policies could translate into public benefits 
(Becker, et al., 2008; Reuter & Pollack, 2006).  
Future Research 
Collectively, this study’s findings are important contributions to the literature.  However, 
probing for deeper meaning into the significant associations (arrest history) with treatment 
utilization is warranted.  Individuals with no history of an arrest should be investigated, 
Collection data on the characteristics of young adults with OUD, in longitudinal studies may 
provide more meaningful results.  Investigating ABM population characteristics among clearly 
defined categories of the young adult population (not in college, varied sexual orientations, 
mental and medical comorbidities, homeless, poverty status) is also needed.  Technological 
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advances should be developed to implement strategies to enhance treatment utilization among 
young adults with OUD.  It is also important to evaluate implementations of recommendations 
made by institutions like NIH to determine whether they translate into increased treatment 
utilization for OUD among young adults in the U.S.  Additionally, future studies should the 
differences between young adults who utilized treatment and young adults who do not utilize 
treatment. 
Summary and Conclusion 
The low treatment utilization among young adults as evidenced in this study is startling.  
Interventions that increase treatment utilization among young adults is essential.  Recognizing 
that young adults in the U.S. have higher treatment needs compared to older adults and the 
highest OUD mortality rates it is crucial that future studies examine population characteristics 
more deeply. MOUDs are available and have been reported to reduce mortality rates.  This study 
analyzed a subset of demographical, social, personal/family and community characteristics as 
posited in the ABM to be associated with treatment utilization.  A hierarchical binary logistic 
regression model is used to analyze associations.  The most important findings are that treatment 
utilization is confirmed to be low among young adults with OUD in the U.S.  In addition, the 
model shows that having an arrest history means the young adult is more likely to utilize 
treatment.  Race/ethnicity, household size and employment status are significantly associated 
with treatment utilization in the bivariate analysis.  Significant population characteristics which 
are modifiable are identified and practical strategies to increase treatment utilization for OUD 
and to reduce the rates of OUD among young adults are recommended.  Policies in place and 




strategies used to address OUD may not be efficient or appropriate for all segments of the young 
adults’ population and needs to be evaluated. 
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APPENDIX A 
PERMISSION TO USE ANDERSEN BEHAVIORAL MODEL 
RE: Requesting permission to use ABM 
From: Ron Andersen 
Sent:  2/25/2019 0:51 
To:    Marva Frederick 
Cc:    randerse@ucla.edu 
Dear Marva, 
You have my permission to use any of my works you use in your dissertation proposal or your 
dissertation itself as long as the works are properly referenced.  Your dissertation is considered a 
publication so I think if you include tables or figures or a long text passage (a page or more?) 
copied directly from the publication, you should probably check with the publishers as well.  If 
you significantly alter or revise the original material you can probably get by with a citation 
explaining how you have altered the original material. 
Best wishes for the successful completion of your dissertation. 
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